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ABSTRACT
Several different peptides exhibit antimicrobial activity based upon an 
am phiphilic a-helical secondary structure. Antimicrobial action occurs 
because these peptides compromise the integrity of the cell m em brane and 
ultim ately cause cell lysis. It is believed that ion-channel formation is the 
m echanism  by which this lysis occurs. The goal of this research has been 
to conduct structure-function studies of synthetic peptides to aid in the 
determ ination of the mode of action of lytic peptides.
Several pep tides based upon  a m inim alist approach  have been 
synthesized. A m phiphilicity and a-helicity were the desired structural 
features. W ith these as the necessary structural m otifs w e set out to 
prepare  peptides w ith very sim ple prim ary structures. This has been 
accom plished in the form of peptides based upon a heptad repeat. By 
altering one residue of the repeat unit, changes can be m ade in the 
secondary structure very easily. Also, the simplicity of the design allows 
for facile large scale preparation  using solution-phase synthesis. The 
design , syn thesis, b iological activ ity , and  secondary  s tru c tu ra l 
determ ination are discussed.
Also, im proved syntheses of benz[/]indene and dibenzfluorenone are 
recounted. These com pounds have been prepared for the synthesis of 
benz-annulated indenyl metal complexes in order to explore the reactivity 
of these unknow n complexes. These complexes m ay exhibit anthracene 
like character and  undergo  D iels-Alder reactions or photochem ical 
couplings at the m iddle rings of the complex. The benz[/]indene ligand
xv
was prepared by two different routes and the dibenzfluorenone by one all 
of which w ere improvements over the published literature syntheses.
xvi
PART I: Synthesis and Structure-Function Studies of 
Repetitive Amphiphilic Lytic Peptides 
CHAPTER ONE: HISTORY OF LYTIC PEPTIDES
1.1 Introduction
N ature has been the source of several antimicrobial peptides. These 
peptides include the m againins1, cecropins 2, and m ellitin.3 Structure- 
function studies have indicated that am phiphilic a-helical secondary 
s truc tu re  is im portan t for the biological activity of these natu ra lly  
occurring peptides.4 Several research groups have synthesized analogs to 
the different families of these amphiphilic a-helical peptides in order to 
understand the conformational requirements necessary to have biological 
activity.5'8
The biological activity of amphiphilic antibacterial peptides is thought 
to arise from the aggregation of peptides in the phospholipid bilayer of the 
cell. Studies suggest that this aggregate is involved in the formation of an 
ion channel which disrupts the bilayer and leads to eventual cell death.9 
These channels are formed w hen individual peptides come together so 
that all the hydrophilic residues face inw ard and  the hydrophobic 
residues face outward. This arrangement allows the hydrophobic residues 
to be in contact w ith the lipid groups of the cell m em brane8 (Figure 1.1). 
Extensive efforts have been directed tow ard the verification of the ion 
channel hypothesis and it has been generally reported that a length of 
twenty residues is necessary to form a trarismembrane channel.10
1
2Figure 1.1 Lateral and Cross Sectional View of an Ion Channel
N aturally occurring lytic peptides are varied according to secondary 
structure. These peptides can be amphiphilic throughout the entire length 
of the helix or simply contain am phiphilic regions. Three well know n 
peptides; magainin, melittin, and cecropin are discussed.
1.1.1 M againin
M againins are a class of basic antimicrobial peptide isolated from the 
skin of amphibians. The first of the m againins w as discovered in 1987. 
Oocytes were surgically removed from the frog Xenopus laevis. The frogs 
were then returned to their aquariums w ithout sterilization of the surgical 
w ounds. After noticing a lack of infection or inflammation on the frogs, 
Zasloff began investigating the source of the antibacterial activity and 
isolated two 23 residue peptides magainin 1 and magainin 2.1 Originally, 
these two peptides were the only m againins11 bu t this family has grown 
to include several other peptides w ith similar structures.7 (Figure 1.2)
Circular dichroism  m easurem ents have show n that m againin 1 is a 
random  coil in aqueous solution but is able to form an a-helix in the
presence of membrane-mimetic solvents such as trifluoroethanol (TFE). 
Magainins 1 and 2 undergo a transition from random  coil in 0% TFE to a 
25% a-helix content in 40% TFE.12 Magainins have also been show n to 
adopt a helical conformation when in contact w ith lipid vesicles. Random 
coil to a - h e l ix  tra n s it io n s  w ere  in d u c e d  b y  d ip a lm ito y l 
phosphatidylcholine, dim yristoyl phosphatidylcholine, and  dipalm itoyl 
phosphatidylglycerol.13
A Schiffer-Edm undson w heel can be used to show  the idealized 
am phiphilic a-helix .14 The helical wheel representation for m againin 1, 
w hich contains eight polar residues along one face of the am phiphilic 
helix, is show n in Figure 1.3. The m againin family exhibits broad 
spectrum  biological activity against both gram-positive and gram-negative 
bacteria as well as fungi and protozoa15 and this antimicrobial activity is 
related to the degree of helicity as is dem onstrated by the activity of 
m againin analogues. M againins B and G have enhanced helicity and 
exhibit higher antimicrobial and antiprotozoan activity than the other 
magainins. On the other hand magainin H, which shows no antibacterial 
or antiprotozoan activity, contains D-alanine in three positions which act 
as helix disrupters.12 To test whether am phiphilicity and  a-helicity, as 
opposed to stereochem istry, are the im portan t s truc tu ra l features, 
magainins containing only D-amino acids have been synthesized. The D- 
magainins have dem onstrated biological activity identical to that of the L- 
magainins. However the D-magainins are more resistant to enzymatic 
degradation than their L-amino acid counterparts due to the presence of 
non naturally  occurring amino acids which are not recognized in vivo 
causing the peptide to remain active for a longer period.16 >X1
4M againin 1: GIGKFLHSAGKFGKAFVGEIMKS-NH2
M againin 2: GIGKFLHSAKKFGKAFVGEIMNS-NH2
M againin A: bAIGKELHAAKKPAKAEVAEIMNS-NH2 
M againin B: GIGKFLHAAKKFAKAFVAEIMNS-NH2
M againin G: bAGIGKFLHSAKKFAKAFVAEIMNS-NH2 
M againin H: GIGKFLHSaKKFaKAFVaEIMNS-NH2 
Figure 1.2 Peptides in the M againin Family
E19
K4, K22
Figure 1.3 Helical Wheel Representation of Magainin 1
The initial interaction of m againins w ith cell mem branes is thought to be 
electrostatic in nature. Experiments perform ed to support this hypothesis 
involve the probing of the interaction of magainin w ith negatively charged
5lipopolysaccharide (LPS) present on the outer membrane of gram-negative 
bacterial cells. M againin causes a disordering of the LPS indicating 
effective binding to the outer leaflet of the cell. Binding is not as effective 
w ith cells containing less LPS.18 Also the activity of magainins have been 
found to be proportional to the LPS concentration.19 Therefore, cells w ith 
less negative charge do not attract the positively charged m againin as 
strongly as cells w ith m ore negative charge. Stronger attraction leads to 
m ore m againin molecules on the cell surface and thus greater am ounts of 
cell lysis.
Secondly, channels are believed to form once the peptide has bound 
to the cell surface. The disruption of the m em brane caused by m againin 
has been m easured using leakage of fluorescent dyes from unim ellar 
vesicles. Different types of vesicles w ith varying negative charges give 
different degrees of fluorescence leakage. Vesicles with a greater negative 
charge exhibit leakage to a larger extent. These results verify the 
im portance of electrostatic interaction betw een the m em brane and 
m againin. Calculations suggest that leakage occurs only w ith  several 
hundred  peptides per cell.20 This is in agreement w ith the hypothesis of 
several peptides aggregating to form a pore.
O ther techniques used by researchers to determine channel formation 
involve electrophysiological m easurem ents. In these experim ents the 
changes in trans-bilayer voltage due to the m ovem ent of ions through 
channels are monitored. M ethods such as these allow the investigation of 
single ion channels to determ ine the num ber of pep tide m onom ers 
necessary to form an ion channel. Electrophysiological studies have 
indicated magainin shows selectivity for anions, believed to be due to the
basic residues lining the pore21, and concentration dependence studies 
indicate an apparent channel of 3-6 monomers per channel.22
1.1.2 Cecropin
The N orth  A m erican silk m oth  Hyalophora cecropia responds to 
bacterial infections by the production of 15-20 proteins including a class of 
antimicrobial peptides known as cecropins. These peptides were isolated 
and their structural and biological properties were examined. Cecropins 
show  broad spectrum  biological activity against both gram  positive and 
gram  negative bacteria while general resistance is shown by eukaryotes 2 
Three cecropins have been isolated; cecropin A w ith 37 residues, cecropin 
B w ith  35 residues, and cecropin D w ith  36 residues. The prim ary  
structure of cecropins contains two distinct regions. The N-term inus can 
be seen to be basic and the C-terminus is more hydrophobic. Com pared 
w ith the other cecropins, cecropin D contains fewer basic residues in the 
N-terminus. The decreased activity of cecropin D is attributed to its low 
basicity and thus lower amphiphilicity in the N-terminus in comparison to 
cecropins A and B. Primary structures for cecropins A, B, and D and some 
analogues are provided in Figure 1.4. Secondary structure determ ination 
has been  carried  ou t in m em brane-m im etic  so lven ts  such  as 
hexafluoroisopropanol (HFIP) and trifluoroethanol (TFE). C ircular 
dichroism studies indicate cecropin A is in a random  coil conformation in 
aqueous solution. On the other hand, cecropin A is approxim ately 60% 
helical in 15% HFIP.23 Cecropins are composed of two a-helical regions 
connected by a hinged region centered at residues 24 and 25, glycine and
proline, which interrupt the helix. The helical wheel representation for the 
two helical regions is shown in Figure 1.5.
Cecropin A: KWKLFKKIEKVGQNIRGDnKAGPAVAWGQ
ATQIAK-NH2
Cecropin B: KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGE
AKAL-NH2
Cecropin D: WNPFKELEKVGQRVDAVISAGPAVATVAQA
TALAK-NH-2
MP1: KWKLFKKIEKVAKKIKEAIEKALEAVAKLLKE
AKEIAK-NH2
MP2: KWKLFKKIEKVAKKIKEAIEKALEAIAVLALA
LAL-NH2
MP3: KWKLFKKIEVGRNGRNGrVKAGPAIAVLALA
LAL-NH2
MP4: KWKLFKKIEKV-NH2
Figure 1.4 Cecropin Peptides and Model Peptide Analogues
HELIX 1-21 HELIX 24-37
Figure 1.5 Helical Wheels of the Two Helical Regions of Cecropin A
The importance of the hinged region separating basic and hydrophobic 
helices has been investigated using a series of m odel peptides MP1 to 
MP4.24 (Figure 1.4) These peptides w ere designed to change the 
secondary structure of the cecropins in specific ways. MP1 is fully a- 
helical and exhibits only m oderate activity in comparison to cecropins A 
and B suggesting that am phiphilicity alone does not account for the full 
activity of cecropins. MP2 on the other hand is lacking am phiphilicity 
and has decreased activity. MP3 is the closest m odel to the cecropins and 
is nearly equivalent to cecropins A and D in activity. MP4 is a shortened 
sequence and has only slight activity indicating the need for both 
segments for cell lysis to occur 25 These observations are consistent w ith 
the proposed mechanism of cecropin induced cell lysis. The first step in 
the in teraction of cecropins and the bilayer is also though t to be 
electrostatic attraction of the peptides to the bilayer surface. As w ith 
m againins, the am ount of negative charge on the bilayer surface plays a 
role in activity. M embranes w ith a positive surface repel the positively 
charged  m olecules as is ev idenced by a low er conductiv ity  in 
electrophysiological m easurem ents.26 The second step  is possibly  
insertion of the hydrophobic portion of the peptide into the non polar 
region of the bilayer. The flexible hinge region m ay then allow  the 
insertion of the positively charged am phiphilic helical region into the 
bilayer follow ed by form ation of a pore. The pore then has the 
amphiphilic region lining the inside of the channel w ith the hydrophobic 
region lining the outside toward the lipid chains (Figure 1.6). The num ber 
of m onom ers required for the form ation of a pore still has yet to be 
determined.
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Figure 1.6 Cross Section of Cecropin in the Bilayer
1.1.3 M elittin
Melittin, a 26 residue peptide, is the m ain com ponent of the venom  of 
the honey bee, Apis mellifera, comprising 50% of the dry venom.27 It is also 
active against both gram positive and gram negative bacteria. However, it 
also causes hemolysis to a large extent. As w ith the previous two peptide 
classes, melittin is amphiphilic and a-helical (Figure 1.7).
M elittin has a largely basic C-term inus as opposed to the basic N- 
term inus of cecropin. Melittin at low peptide concentration and low ionic 
strength exists as a m onom er and in solutions of high ionic strength it 
aggregates into a tetram eric form. The monomeric state exhibits little 
secondary  s tru c tu re  according to circular d ichroism  experim ents 
conducted in solutions of low ionic strength.23 On the other hand, the
10
Figure 1.7 Melittin: GIGAVLKVLTTGLPALISWIKRKRNN-NH2
solid state structure of the tetram er has been exam ined using X-ray 
diffraction and can be seen to be up  to 90% a-helical.29'30 Circular 
dichroism  experiments show a-helical content betw een 50-60% .31 The 
differences between the a-helical content in the solid state and the solution 
state can be attributed to solvent interactions w ith polar residues.32 The 
tetram er has two units perpendicular to each other. The two units are 
composed of two m onom er peptides antiparallel to each other. In this 
conform ation all the hydrophobic faces are in close contact w ith  one 
another stabilizing the tetram er. The contact betw een m onom ers is 
exclusively hydrophobic and the side chains can be seen to be highly 
interlaced. A globular aggregate w ith a highly charged exterior (+24) and 
a hydrophobic interior is the resu lt29'30 In solutions of low ionic strength, 
positive charges w ould not be as stable as in h igher ionic strength  
solutions and  charge repulsion w ould inhibit aggregate form ation.
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H ow ever, in higher ionic strength solutions, the charge stability gained 
w ould  allow the hydrophobic interaction to dom inate. Based on these 
assum ptions, Terwilliger and Eisenberg have proposed the following 
about the delivery of the toxin from the bee to the membrane: in the 
venom  sac the peptide is at a concentration of approximately 20 mM and 
is thus in the tetrameric form. Under physiological conditions the peptide 
is diluted to concentrations of roughly 200 pM w here the monomeric and 
tetram eric forms are about equally distributed and only 1 /1 0 0 0  of this 
concentration is needed to cause 50% hemolysis. Therefore, they propose 
the m onom er is the active form .29'30
M elittin has two m ain actions, a direct lytic effect and an indirect lytic 
effect. It lyses directly phospholipid vesicles and all cells on which it has 
been tested as well as intracellular organelles including lysosomes and 
m itochondria .29'30'33 The indirect lytic effect arises from the activation of 
phospholipase present in the bee venom after interaction of melittin w ith 
the bilayer. The phospholipase causes further cell lysis and destruction 32
M uch research has been directed toward determ ining the structure of 
m elittin in the m embrane and the relation to biological activity. Circular 
dichroism 28,34 and tryp to p h an  19 fluorescence35 have been used  to 
determ ine secondary structure in vesicles as m em brane models. These 
studies agree that melittin adopts a secondary structure similar to that of 
the monomer units in the tetramer, i.e., a-helix. However, the aggregation 
state of melittin in the membrane is a point of contention among different 
groups. Monomers, dimers, and tetramers have often been proposed .35,36 
The fluorescence studies show that the tryptophan only penetrates slightly 
into the m em brane .35,37 This indicates that melittin in the membrane may
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exist in a raft conformation where the peptide is in a horizontal orientation 
w ith the polar residues tow ard the negatively charged head groups of the 
m em brane (Figure 1.8).
Figure 1.8 Peptide in a raft conformation
Two different m odes of action are proposed for melittin. One is the 
previously discussed oligomeric channel or pore that produces osmotic 
lysis. Tosteson observed the osmotic reversal of lysis which is consistent 
w ith this mechanism .38 The second proposed mechanism of lysis involves 
sim ple disruption of the phospholipid bilayer w ithout channel formation. 
This m ode of action m ay or m ay no t involve osm otic lysis. The 
observation of peptide rafts w ith the peptide only penetrating a few 
angstrom s into the bilayer supports this model.
1.2 Synthetic Lytic Peptides
The apparent im portance of am phiphilicity for the activity of the 
naturally  occurring peptides has prom pted several research groups to 
p repare  synthetic peptides designed to adopt am phiphilic secondary
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structures. For the most part these synthetic peptides have been designed 
and synthesized for the purpose of identifying w hat features are necessary 
for activity. Analogs of naturally  occurring peptides, hybrid peptides 
com posed of sections of different naturally occurring peptides, and de 
novo peptides have been prepared.
1.2.1 Peptide Analogs
In addition to the previously discussed analogs synthesized by other 
research groups, Jaynes has prepared analogs to cecropin, m elittin, and 
magainin. Magainin-like peptides (Anubis series) were synthesized with 
the potential to form an amphiphilic a-helix along the entire length of the 
peptide. Cecropin-like peptides (Shiva series) are am phiphilic and a- 
helical at the N-term inus of the peptide. Finally, melittin-like peptides 
(Hecate series) are designed to show amphiphilicity and a-helic ity  at the 
C-terminus. (Figure 1.9)
The Shiva, Hecate, and Anubis peptides were designed to be similar to 
the native peptides but are not homologous. Jaynes found that the native 
peptides not only lysed microbes but also lysed transform ed mammalian 
cells as well. Biological activity for the analog peptides was greater than 
the native peptides in all cases except melittin. However, Hecate did not 
lyse norm al m ammalian cells as did melittin. Because the peptides were 
not hom ologous w ith the naturally occurring peptides, the m ain feature 
these peptides had in common were their regions of amphilicity. These 
results support the prem ise that am phiphilicity and a-helicity are the 
im portant structural features for activity.
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Magainin class
amphiphilic throughout
GIGKFLHSAKKFGKAFVGEIMNS Magainin [23]
FAKKLAKKLAKKLKKLAKLAKKLAKKLKKLAKKLAKLA Anubis series
Anubis-2 [23] Anubis-3 [31] Anubis-4 [38]
Cecropin class
amphiphilic head
KWKVFKKIEKMGRNIRNIVKAGPAIAVLGEAKAL Cecropin B [35]
MPRWRLFRRIDRVGKQIKQGILRAGPAIALVGDARAVG Shiva-1 [38] 
FAKKLAKKLKKLAKKLAKLALALKALALKALALKALAL Shiva series
Shiva-10 [23] Shiva-11 [31] Shiva-10 [38]
^ALAKLA
M elittin class
amphiphilic tail 
GIGAVLKVLTTGLPALISW1KRKRQQ Melittin [26]
AKLALAKLALALKALKKALKKLKKALKKAL Hecate series
Hecate-3 [38] Hecate-2 [31] Hecate-1 [23]
Figure 1.9 Native and Anubis, Shiva, and Hecate series peptides
1.2.2 Peptide hybrids
H ybrids of naturally  occurring peptides have been prepared  in an 
effort to obtain peptides w ith greater antimicrobial activity than the parent 
peptides yet less hemolytic. Several peptides composed of m elittin and
cecropin sections have been synthesized. The activities of the peptides 
obtained are interm ediate to the activity of the parent peptides bu t w ith 
hemolytic activity less than that of melittin .39 (Table 1.1)
Table 1.1
Lethal Concentrations (|iM) for Cell Lysis w ith Cecropin-Melittin Hybrids
Parent peptides EC PA SA SRC
CA(l-3 7) 0.2 4 >200 >200
M(l-26) 0.8 0.2 0.2 4-8
Hybrid peptides
CA(1-24)M(1-13) 0.3 0.5 6 >200
CA(1-13)M(1-13) 0.5 0.7 2 >200
CA(25-37)CA(1-13) 200 20 >300 >300
M(1-13)CA(1-13) 1 0.3 5 80
M(16-26)M(1-13) 0.7 0.7 10 >200
CA, cecropin A; M, melittin; EC, Escherichia coli; PA, Pseudomonas aeruginosa; SA, 
Staphylococcus aureus; SRC, sheep red blood cells
1.2.3 Synthetic Lytic Peptides
M any research groups have synthesized peptides designed to mimic 
the behavior of naturally  occurring peptides b u t are not analogs of 
naturally  occurring peptides (de novo peptides). These m odel peptides 
have been prepared in order to shed light on the structural requirem ents 
necessary to lead to biological activity or ion conductance. M inimalist 
peptides w here the peptide backbone is composed of only a few different
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types of am ino acid residues are m uch sim pler structures than naturally 
occurring peptides yet are still biologically active suggesting that lysis is 
sequence independent. Two minimalist peptides composed of only serine 
and leucine residues and based on a heptad repeat have been synthesized 
by DeG rado .40 The peptides were 21 residues or three heptad units long 
(the length necessary to span the phospholipid  bilayer. The hep tad  
sequence (LSSLLSL) w as chosen to maximize the peptides am phiphilic 
character while (LSLLLSL) was chosen to provide a large leucine face in 
o rder to form a tetram eric coiled-coil form as found in the four helix 
bundle Col E l Rop .27 However, the (LSLLLSL)3 tetrameric bundle has a 
hydrophilic interior and a hydrophobic exterior as opposed to Col E l Rop 
w ith a hydrophilic exterior and a hydrophobic interior. Serine was chosen 
as the hydrophilic residue because it is the smallest of the polar amino 
acids and w ould leave a larger cavity in the interior of a channel for ion 
transport. Leucine was chosen for the non polar residues because its 
s trong  hydrophobic interaction m ight aid in the bund le  form ation. 
Molecular models of the tetrameric bundle show a channel large enough 
to accom m odate indiv idual w ater m olecules bu t too sm all to allow 
hydrated  alkali metals. Indeed, this peptide has been show n to form 
proton specific channels and no transport of alkali metal cations .10
The second peptide, w ith m axim um  am phiphilicity, does not lend 
itself to tetram eric coiled-coil form ation. W hen m odeled as a four 
stranded structure, two serines per heptad extend into the interior of the 
pore but the third serine is at the interface between strands disrupting the 
hydrophobic leucine-leucine interaction. Alternatively, a six stranded 
bundle allows all the serines to be in the interior of the pore. This peptide
17
was found to allow conductance of hydrated cations of 8 A diameter and 
less.10
Since it is difficult to determ ine conformation of the peptides while in 
the channel. DeGrado et. al. designed a peptide based on the above 
structure that has even greater helicity. The new  pep tide had  the a- 
am inoisobutyric acid (Aib) residue incorporated into the 4,11, and 18 
positions of the (LSLLLSL)3 sequence to give (LSLBLSL)3 . Aib has been 
found to constrain peptides into 3io- helical or a-helical conformations 
and in pep tides longer than  15 residues the a-helical conform ation 
appears to be favored .24 The conductance states of both the (LSLLLSL)3 
and the (LSLBLSL)3 peptides are nearly identical indicating that the ion 
channels are of a similar structure. This channel is probably composed of 
a-helices based on the (LSLBLSL)3 peptide results.
W ithout a transm em brane voltage, the peptides lie in an orientation 
parallel to the surface of the bilayer. To explore the conformation of the 
(LSSLLSL)3 peptide under these conditions, DeGrado et. al. incorporated 
a tryptophan successively into each position of the central heptad. The 
fluorescence em ission  spec tra  of the  p e p tid e  in se rted  in to  a 
diphytanoylphosphatidylcholine bilayer was m easured. Lower values of 
tryptophan emission maximum means the tryptophan is in a hydrophobic 
environment. Results indicate that the serine is located near the surface of 
the bilayer in a hydrophilic environm ent and leucines are tow ard the 
inside  of the b ilayer in  a hydrophob ic  env ironm ent. W hen a 
transm em brane voltage is applied the peptide flips to the m em brane 
spann ing  conform ation. Presum ably, pep tides in transm em brane 
conformation then aggregate to form the ion channels.8
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A series of peptides based on the classically am phiphilic a-helix Ac- 
LK LLK K LLK K LK K LLK K LN H 2 w ere prepared  by H oughten et. al 
(Figure 1.9). Three series of analogs, and chain length analogs, w ere 
p repared  to test biological activity vs. reverse phase-high perform ance 
liquid chrom atography (RP-HPLC). The interaction of peptides w ith the 
s ta tio n ary  phase  in RP-HPLC are considered  to be sim ilar to 
pep tide/m em brane interactions in biological processes. Retention time 
and hemolytic activities of melittin analogs were found to be correlated .3 
Studies indicate that Ac-LKLLKKLLKKLKKLLKKLNH2 is induced into 
an amphiphilic a-helix due to interaction with the solid phase .25,30 For the 
omission analogs, each residue was om itted successively and biological 
activ ities m easured. U nexpectedly, it w as found that increased 
antim icrobial activity and  decreased hemolytic activity was obtained 
w hen the hydrophobic face of the peptide was disrupted by the omission 
of residues L-7, K-9, K-12, or L-14. Thus, apparently a hydrophobic face of 
only 5 contiguous residues is sufficient for cell lysis.
Substitution peptides were prepared where each residue was replaced 
by the residue of opposite polarity  (e.g. Leucines w ere replaced by 
lysines). Here, it was also found that sequences w ith smaller hydrophobic 
faces had increased antimicrobial activity. The peptides w ith smaller 
hydrophobic faces w ould be expected to have lower RP-HPLC retention 
tim es due to weaker p ep tid e /so lid  phase interactions. Experim ental 
observations were consistent with this expectation.
A nalogs w ith  length  varying from 8-22 residues, shortened  or 
lengthened from  the N -term inus of the paren t pep tide , w ere also 
prepared. Historically, it has been proposed that the m inimum length
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Figure 1.10 Helical Wheel of Ac-LKLLKKLLKKLKKLLKKL-NH2
required for biological activity is 20 residues. 20  residues are necessary to 
span the lipid bilayer. However, the highest antimicrobial activity was 
obtained for 14 and 15 m er sequences. These peptides also had  lower 
hemolytic activity.
A series of m odel peptides term ed "modelins" w ere synthesized by 
Bessalle, et. al. to probe the effect of length and  am phiphilicity  on 
antim icrobial activity. Eleven peptides from  9 to 17 residues w ere 
p r e p a r e d .  T h e  p a r e n t  s e q u e n c e  m o d - 1  H-
LysLeuTrpLysLysTrpAlaLysLysTrpLeuLysLeuTrpLysAlaTrpOH is an 
amphiphilic helix. The hydrophobic character was changed by replacing 
all Trp residues w ith less polar residues like Leu or Ala and by replacing 
Trp w ith  ano ther h ighly  hydrophobic residue like phenylalan ine. 
Hydrophilic character was altered by replacing Lys w ith the less charged 
residue histidine, shortening by one residue (lysine-8) to give a 16-mer,
20
and by increasing Lys content from 7 to 10. Shorter peptides (9 and 10- 
mers) w ere synthesized by perform ing sim ilar m odifications to those 
above based on the first 10 residues of m od-1 . A m phiphilic 10 m ers 
composed of 5 Lys w ith 5 Trp or 5 Leu were prepared. Finally a 9 mer 
devoid  of am phiphilic character was prepared . The 16 and 17-mer 
peptides w ere a-helical in 50% TFE w here as the 9 and 10-mer peptides 
w ere not a-helical. The highly hydrophobic m odelins (the 17-mers w ith 
Trp and Phe) were highly hemolytic. The peptides w ith less hydrophobic 
residues were not as active against microbes bu t were less hemolytic. The 
Lys containing peptides were more active than the histidine containing 
peptides. Finally, the shorter peptides are m uch less active than the 
longer peptides. Thus, Bessalle et. al. propose that peptides containing 
some degree of am phiphilicity and containing highly charged residues 
like Lys m ight show antimicrobial and hemolytic activity.6
The highly charged residues in the 16 and 17 mer peptides of Bessalle 
and in the 14 and 15-mers of Houghten aid in the initial interaction of the 
peptides w ith the negatively charged surface of the bilayer. With naturally 
occurring lytic peptides this is also the proposed initial interaction. This is 
followed by pore formation from the aggregation of membrane spanning 
peptides. However, Their shorter length does not allow them to span the 
m em brane while in an a-helical conformation. Simple disruption of the 
bilayer by the penetration of the hydrophobic portions of the peptides, 
p ep tid e  channels com posed of 3io helices w hich could span  the 
m em brane, head to tail dim ers of peptides w hich aggregate to form  
transm em brane channels, or channels that span  a portion  of the 
membrane may be the source of the lytic activity.
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1.2.4 TASP Molecules
The activity  of lytic pep tides m ay be increased by delivering  
preform ed channels to the cell. A possible m ethod of achieving this goal 
is the use of tem plate-assem bled synthetic proteins (TASP). For the 
construction, of TASP molecules, a tem plate w ith linker groups that can 
easily form covalent bonds w ith peptides is used. For ion conductance 
this template should have a large enough cavity to allow ion conductance.
M utter et. al. have succeeded in synthesizing 4-helix bundle TASP 
m olecules by synthesizing linear and cyclic carrier pep tides as the 
tem plates. The e-N of Lys in the tem plate backbone are the site of 
attachm ent of the a-helical peptides. Initially, M utter grew the peptides 
from  the tem plate using step-wise solid phase synthesis .41 However, 
problem s w ith  m icroheterogeneity w here pep tide  chains m ay differ 
slightly due to deletion sequences or insertion of an extra residue arise. To 
overcom e this problem  M utter has p repared  cyclic tem plates and 
condensed them w ith fully protected peptides followed by deprotection. 
This assures that all the attached chains will be the same. HPLC of the 
products indicate that large quantities of fully coupled m aterial were 
obtained. Thus the high num ber of reaction sites does not adversely effect 
the coupling efficiency.42
Since m olecular m odeling indicates that DeGrado's proton selective 
channel (LSLBLSL)3 is a tetram eric bundle, attem pts w ere m ade to 
prepare a TASP molecule. Earlier w ork showed that a-helical bundles 
could assemble around coproporphyrin. DeGrado chose tetraphenyl 
porphyrin as a more rigid template. Molecular modeling suggested that
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tetraphenyl porphyrin  w as reasonable for the covalent linkage of four 
molecules of (LSLBLSL)3 . Condensation of (LSLBLSL)3 w ith the template 
yielded tetraphilin-1. Tetraphilin-1 forms pro ton  selective channels in 
d iphytanoylphosphatidylcholine as w ith  (LSLBLSL)3 . H ow ever, the 
channel lifetime is m uch longer w ith Tetraphilin-1. Also, the channel 
form ation of Tetraphilin-1 is nearly voltage independent as opposed to 
channel fo rm ation  of (LSLBLSL)3  w here the pep tide  is in a raft 
conform ation w ithout applied voltage. These results indicate that the 
tem plate exhibits a strong stabilizing effect on the channel conformation 
presum ably due to the geom etry requirem ents of the TASP leading to 
differences in hydrophobicity .42
CHAPTER TWO: SOLUTION-PHASE PEPTIDE 
SYNTHESIS
2.1 Introduction
Initially, our group became involved w ith lytic peptides to synthesize 
oc-aminoisobutyrie acid (Aib) containing analogs of peptides prepared by 
Dr. Jesse Jaynes. The goal was to obtain peptides constrained in a-helical 
conformations due to the presence of a,a-dialkylated residues and to slow 
dow n enzym atic hydrolysis in vivo because of the xenobiotic residue. 
How ever, we soon realized that Aib incorporations are difficult in both 
solid-phase and solution-phase peptide couplings .43 Incorporation into 
several sites along the peptide backbone via a linear approach w ould be 
an extremely difficult task.
To circum vent this problem  we designed peptide sequences that are 
m uch sim pler yet are still am phiphilic and highly charged. Using an 
Edm undson helical w heel14 we designed highly repetitive peptides that 
w ould m inim ize the num ber of difficult couplings due to a fragm ent 
coupling approach. As did DeGrado, we discovered that heptad repeats 
can lead to classically amphiphilic peptides. This convergent approach 
takes advantage of the repetitive nature of heptads in a-helices as well as 
repetition w ithin the heptad. A heptad unit in an a-helix is 700°, which is 
nearly  tw o revolutions around the helix. Peptides w ith  the general 
sequences (PNNPNNP)n and (PNNPPNN)n where P=polar residue and 
N =non polar residue have been prepared (Figure 2.1). These sequences 
are isomers yet have different size polar faces. For example, the two 21-
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m er sequences composed of three heptads lead to 180° and 160° polar face 
sizes respectively.
N 9180° Polar 
Face
i»P
160° Polar 
Face
(PNNPNNP)3 (PNNPPNN)3
Figure 2.1 Edm undson Wheel Diagrams of General Peptide Sequences
The hep tad  repeat design is advantageous because a convergent 
synthetic approach can be used for the peptide synthesis (Figure 2.2). The 
peptide can be synthesized via solution phase peptide synthesis by using 
fragments of the target peptide rather than in a linear fashion one residue 
at a time. This is advantageous because larger quantities of peptide can be 
obtained due to increased overall yield.
To test w hether these pep tid e  designs w ould  p ro v id e  viable 
biologically active peptides, we have synthesized a series of peptides from 
7-28 residues (not containing Aib) via solid-phase peptide synthesis. A 
suitable sequence was chosen as a target for the solution-phase synthesis
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to dem onstrate the effectiveness of the convergent approach. Biological 
activity, structural studies, and solid-phase synthesis will be discussed.
( P N N P N N P ht
PNNPNNP + PNNPNNP
i
P + NNPNNP
t
NNP + NNP
t
P + NN
t
N + N
Figure 2.2  Pathway for Convergent 14-mer Synthesis
2.2 Peptide D esign
The hep tad  repeat allows changes to be m ade in the pep tide very 
easily w ithout disrupting the amphiphilicity. We have prepared several 
peptides by systematically changing the num ber of residues, the order of 
the residues, and the types of residues to determ ine if there is sequence 
dependence for biological activity. However, som e things w ere kept 
constant w ith in  each peptide. Each sequence is highly charged and 
contains the same num ber of polar residues per heptad. Each is classically 
am phiphilic and is theoretically capable of forming pores in m em branes 
w ith  the polar residues lining the interior and hydrophobic residues
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facing outw ard into the phospholipid bilayer. We have prepared peptides 
w ith different sized polar faces top see if this structural difference w ould 
effect the biological activity.
2.2.1 (LysLeuAlaLysLeuAlaLys>3
Initially, we designed peptides composed of three heptads so that the 
length of the peptide w ould be sufficient to span the lipid b ilayer .10 
Lysine was chosen as the polar residue because it is fairly easy to couple 
and is positively charged. Bessale et al. also indicate that lytic peptides 
containing lysine are m ore active than peptides w ith  other charged 
residues such as histidine .6 Two types of non polar residues were chosen. 
Leucine w as selected for its ease of coupling and its hydrophobicity  
favoring interaction w ith the bilayer. Also, literature results indicate that 
w ith  leucine as the hydrophobic residue, the peptides m ay be less 
hemolytic than peptides w ith phenylalanine or tryptophan .6 Alanine was 
chosen to u ltim ately  aid  in the so lu tion-phase synthesis. It is 
hydrophob ic , easier to couple than  leucine, and  shou ld  reduce 
racemization problems in fragment couplings. All three of these residues 
are frequently  found in helical peptides w hich w as an add itional 
consideration leading to their selection .44 This sequence is classically 
amphiphilic with a 180° polar face (Figure 2.3).
Since aggregation in the m em brane is apparen tly  necessary for 
biological activity, we sought to induce aggregation via a special type of 
hydrophobic interaction know n as the "leucine zipper". This is an 
additional reason we began our research with 21-mers (Figure 2.3).
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(LysLeuAlaLysLeuAlaLys) 3
(PNNPNNP) 3
Leu
2° positions
LysLys Leu
LeuLys
Lys Leu
Leu 1° positions
180° polar face
Leu 2
Ala
AlaLys
Lys Ala
Ala Ala
Ala
Lys
Figure 2.3 Edm undson Helical Wheel Representation of (KLAKLAK)3
A leucine zipper is formed w hen leucines occur every seventh residue 
w ithin a a-helical peptide. Two helices dimerize from the interdigitation 
of one helix w ith  the next. The zipper is stabilized by the presence of 
secondary leucines four residues aw ay from  the p rim ary  positions 
p ro v id in g  a large hydrophob ic  face for hydrophob ic  in teraction. 
N aturally occurring zipper peptides contain at least four leucines in the 
prim ary positions .45,46 We have synthesized peptides w ith fewer leucines
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in the hope that w e m ay still obtain aggregates. If not, we still have 
classically amphiphilic peptides.
2.2.2 (LysAlaLeuLysAlaLeu) 3
This pep tide also has a 180° polar face and w as designed to test 
w hether activity is sequence dependent. The difference betw een these 
two peptides is that the positions of the leucines and alanines has been 
switched. A potential leucine zipper is still present w ith three tines and 
two secondary positions filled (Figure 2.4).
(LysAlaLeuLysAIaLeuLys) 3  
(PNNPNNP) 3
Ala
Lys
AlaLys
AlaLys
Lys Ala
(ULys Ala
180° polar face
Ala 2
Leu
.Lys Leu
Lys Leu
2° positions
Leu LeuLeu
Lys
1° positions
Figure 2.4 Edm undson Helical Wheel Representation of (KALKALK)3
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2.2.3 (LysLeuAlaLysLysLeuAla>3
By m oving the lysine at the seventh position w ithin the peptide to  the 
fourth position, two modifications are made. The peptide now  has a 160° 
polar face and all secondary positions are filled in the leucine zipper. This 
peptide has the same num ber of positive charges w ithin its polar face as 
the previous 21-mers , however, the polar face is narrower. We prepared 
this peptide to determine if this change produces an appreciable difference 
in biological activity. If the biological activity for this peptide is greater 
than that of its isomer, it w ould be a better candidate for solution phase 
synthesis because it has alanines at all fragm ent coupling sites w hich 
should reduce racemization (Figure 2.5).
(LysLeuAlaLysLysLeuAla) 3 
(PNNPPNN) 3
&
Lys
Lys Lys
LysLys
Lys Leu
160" polar face
Leu 1 ° positions|11Lys
18 Lys Leu 2
Leu
A la Leu
Ala Leu
Ala 2 ° positionsAlaAla
Ala
Figure 2.5 Edmundson Helical Wheel Representation of (KLAKKLA)3
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2.2.4 (LysLeuGlyLysLysLeuGly)3
This peptide also has a 160 ° polar face and all secondary positions are 
filled. A lanine has been replaced by glycine. The reason for this 
replacem ent is twofold. First glycine has been seen to be an a-helix 
d is ru p te r .44 Therefore, we incorporated glycine into this sequence to 
determ ine if helicity is indeed reduced and if biological activity is also 
lessened. Secondly, glycine is at all fragm ent coupling sites if solution- 
phase synthesis w ere to be em ployed. Since glycine is non chiral, 
racemization w ould not be a problem (Figure 2.6).
(L ysL euG lyL ysL ysL euG lyk
(P N N P P N N )3
©
L y s
L y s L ys
L ysL ys
[4 L ys Leu
160" polar face
1° positionsiL y s Leu
Leu 2
Leu
G ly
,7
Leu
G ly Leu
2" positions
G ly
Figure 2.6 Edm undson Helical Wheel Representation of (KLGKKLG)3
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2.2.5 (LysLeuAlaLysLeuAlaLys)2 and (LysLeuAlaLysLysLeuAla)2
To explore the importance of length on lytic peptide activity we have 
p rep ared  a series of pep tides w ith  tw o general hep tad  sequences; 
(KLAKLAK)n and (KLAKKLA)n (Figures 2.7 and 2.8)- Just as before these 
two sequences lead to different sized polar face w ith the angle depending 
on the num ber of heptads. Synthetic lytic peptides that are m ore active at 
lengths of less than  20  residues than  their longer analogs have been 
p repared .6'7 The first sequence we prepared, (KLAKLAK)2, has a 160 ° 
polar face but is too short to form leucine zippers. The 14-mers m ay also 
be less helical than the 21-mers.
(LysLeuAlaLysLysLeuAla) 2 
(PNNPPNN)2
i i  \  ■, \ f  12
Lys) V y y (Lys
L y s
L y s
140” polar face
L e u 9iL y  s
Leu
A la L eu
13.
A la Leu
A la
A la
10
Figure 2.7 Edm undson Helical Wheel Representation of (KLAKLAK)2
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The second 14-mer has a 140 0 polar face. If this 14-mer is as active as 
the previous peptides than it w ould  be selected for solution phase- 
synthesis since it would require less steps to prepare.
(LysLeuAlaLysLysLeuAla)2
(PNNPPNN)2
L y s
L y s L y s
L y s
L y s
140° polar face
L e u 9
L eu  2
A ! L eu
A la L eu
A la
A la
Figure 2.8 Edm undson Helical Wheel Representation of (KLAKKLA)2 
2.2.6 (KLAKLAK)4 and  (KLAKKLA>4
We felt that increased aggregation due to hydrophobic interactions 
from a full leucine zipper could possibly lead to peptides w ith increased 
activity. Therefore, we prepared 28-mers based on the general heptad  
repeat units. Figure 2.9 show s the helical w heel representation  of 
(KLAKLAK)4 which has a 200 0 polar face and a four tine leucine zipper.
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(LysLeuAlaLysLeuAlaLys) 4
(PNNPNNP) 4
2° positions
Leu
Leu
Lys LeuLys Leu
LeuLys
1° positionsLys
Lys Leu
AlaLeuI11 Lys 27
200 0 polar 
face
(i8Lys Leu 2
Ala
20
Lys Ala
Lys Ala
Ala Ala
1^7.Ala
.10
Ala
Lys
Lys
Figure 2.9 Edm undson Helical Wheel Representation of (KLAKLAK)4
A second 28-mer, (KLAKKLA)4 has been p repared  as well. This 
peptide has a 180 ° polar face and a four tine leucine zipper (Figure 2.10).
2.3 Results and  Discussion
2.3.1 Solid Phase Synthesis
Solid phase synthesis led to the desired peptides. The solid-phase 
m ethodology w e em ployed w as autom ated peptide synthesis. This 
process involves a polymeric support functionalized w ith a linking group.
34
(LysLeuAlaLysLysLeuAla) 4
(PNNPPNN) 4
Lys
Lys
23
LeuLysLys Lys
LysLys
1° positionsLys
Lys Leu
180° polar face
Leu 2
Leu
LeuAla 2° positions
Lys
Ala Leu
Ala Ala
Ala Ala 
. 24
A la^
Ala
Figure 2.10 Edm undson Helical Wheel Representation of (KLAKKLA)4
The first amino acid is attached to the resin via an am ide bond. Each 
am ino acid is then subsequently  attached to com plete the desired  
sequence. The amino acids are protected on the a-nitrogens and on side 
chains if necessary to prevent further undesired chain growth. The acid is 
activated to provide for easier and higher yielding couplings. The a- 
nitrogens and the side chains have different protecting groups that are 
rem oved u n d er d ifferent conditions. This technique is know n as
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orthogonal p ro tec ting  groups. In our syn thesis  w e have used  
fluorenylm ethoxycarbonyl (FMOC) as the oc-nitrogen protecting group. 
FMOC is a base labile group, rem ovable by a p iperid ine w ash. £- 
N itrogens on lysines are protected w ith tert-butyloxycarbonyl (t-BOC) 
w hich is an acid labile protecting group rem oved by treatm ent w ith 
trifluoroacetic acid (TFA). The TFA w ash also removes the peptide from 
the resin. The activating group for the acid is a pentafluorophenyl ester 
which is a good leaving group. By using an orthogonal protecting scheme 
it is possible to deprotect the N-terminus of the peptide w ith a piperidine 
w ash and leave the side chain protecting groups in place preventing 
peptide growth off the side chains.
After final deprotection and cleavage from the resin w ith  TFA, the 
peptides have been purified by two different procedures. In the first 
m ethod the peptides are precipitated from the TFA cleavage cocktail by 
dropping into ether. The precipitated peptide is centrifuged and dried. 
The solid is dissolved in aqueous acetic acid and gel filtered on sephadex 
G-15 to remove low molecular weight material. The desired fractions are 
lyophilized to yield crude peptide which is purified by RP-HPLC. In the 
second m ethod, the peptide dissolved in the TFA cleavage cocktail is 
diluted w ith 20% acetic acid and extracted w ith ether. The aqueous layer 
is lyophilized and the crude peptide is purified by RP-HPLC.
2.3.2 CD M easurem ents
O ur peptide designs are only amphiphilic if the peptides adopt an a- 
helical secondary structure. We have taken the circular diehroism  (CD)
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spectra of these peptides to ascertain w hat kind of secondary structure is 
present for each. These experiments have been performed in two different 
environm ents. Initial CD experim ents w ere taken in the m em brane 
mimicking solvent trifluoroethanol (TFE). Peptide concentration was held 
constant while the TFE concentration varied. These m easurem ents were 
taken on all the 21-mers and each peptide w as seen to adopt a helical 
conformation in aqueous TFE. Initially, each peptide was in a random  coil 
conformation in aqueous buffer at 0% TFE. Even the glycine containing 
peptide adopted an a-helix which we were concerned may not. Therefore, 
we felt that in a m embrane our peptides w ould probably exist in a helical 
conformation.
H ow ever, we felt an environm ent m ore closely resem bling the 
m em brane w ould be a better test of the peptides active conformation. CD 
data in micelles for native peptides have been performed. Thus we also 
m easured the CD spectra of the peptides in sodium  dodecylsulfate (SDS) 
micelles. Since the micelles have a non polar interior.and a polar exterior 
they should be an appropriate m odel for the cell membrane. Again the 
peptide concentration w as constant while the SDS concentration varied. 
These experim ents w ere  perfo rm ed  on the 7,14,21,and  28-m er 
(KLAKKLA)n peptides series. The 14, 21 , and 28-mers were all random  
coils w ith no micelle present bu t adopted a helical conform ation upon 
micelle addition. However, the 7-mers remained random  coil even at high 
micelle concentration. Based on these results, we were confident that our 
pep tides, w ith  the exception of the 7-mers, w ould  be helical in 
m em branes. CD data for the TFE and SDS micelle experim ents is 
provided in Appendix A.
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2.3.3 Biological Activity
These peptides w ere assayed against both Gram(+) and  Gram(-) 
bacteria. Assays of naturally occurring lytic peptides were also performed 
as a comparison to the activity of the synthetic lytic peptides. M inimum 
inhibitory concentrations47 and sublethal doses48 are reported in Table 2.2. 
These pep tides w ere assayed against Escherichia coli, Pseudomonas 
aeruginosa, Staphylococcus aureus, 3T3 cells (healthy m ouse em bryo cells) 
and  3T12 (transform ed m ouse em bryo cells). M inim um  inhibitory 
concentrations were obtained by the broth microdilution method. Peptide 
solutions were prepared over a w ide range from 256 pg /m L  to 2 pg/m L. 
5 x 1()4 cells w ere added to the peptide solutions in sterile wells and 
incubated overnight. Wells in which the organism  has grow n becomes 
turbid. The m inimum inhibitory concentration is the lowest concentration 
w here the well containing cell cultures rem ained clear as visible to the 
naked eye. This is the lowest concentration that inhibited the grow th of 
the organism.
The sublethal dose of the peptide series (KLAKKLA)n w as m easured 
against 3T3 and 3T12 cells. Dilutions of peptide were prepared to allow a 
range of concentrations to be tested. An equal volume of peptide solution 
and 250-750 cells were added. The cells were incubated for 30 m in at 37 
°C. 50 pL of Trypan blue stain was added to each well. Light microscopy 
revealed cells w ith stained nuclei indicating cell death. Sublethal dose is 
defined as the highest concentration in which at least one cell nucleus is 
not stained indicating the presence of live cells as can be seen using light 
microscopy.
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Table 2.2
M inimum Inhibitory and Sublethal Concentrations (|J.M) for Bacterial and
Mouse Embryo Cell Lysis
Peptide E. coli P.
aeruginosa
S. aureus 3T3 3T12
(KLAKKLA) >100 >100 >100 N.L N.L
(KLAKKLA)2 6.0 3.0 6.0 394 788
(KLAKKLA)3 4.2 4.2 4.2 9 17
(KLAKKLA)4 9.0 9.0 9.0 13 52
(KLAKLAK) >95 >95 >95
(KLAKLAK)2 5.8 5.8 5.8
(KLAKLAK)3 3.7 3.7 3.7
(KLAKLAK)4 9.4 9.4 9.4
KALKALK)3 3.9 3.9 7.8
(KLGKKLG)3 3.4 3.4 3.4
magainin 2 1.3 0.65 1.3
melittin 0.56 2.3 0.56
cecropin B 0.20 0.20 1.7
2.4 Experimental
G eneral M ethods: The solid-phase peptide synthesis w as perform ed 
on a M illigen 9050 pep tide synthesizer w ith  a PEG-PAL resin using 
commercially available amino acids already protected as the FMOC forms 
w ith  the carboxylic acid activated as the OPfp ester. Lysines w ere 
protected at N 6 w ith a t-BOC. Each acid came in pre-w eighed vials 
containing 0.792 mmol (four fold excess) of the derivatized am ino acid.
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The peptides w ere assayed against ATCC strains of Escherichia coli 25922, 
Pseudomonas aeruginosa 27853, Staphylococcus aureus, 3T3, and 3T12 cells. 
CD spectra were obtained using an AVIV 62DS spectrophotom eter w ith a 
w avelength range of 255-190 nm  and sam pling every 0.5 nm. Peptide 
spectra were taken at 25 °C. Each spectra is composed of the sum  of two 
scans m inus the spectrum  of buffer. HPLC were obtained on a W aters 
600E instrum ent using a Reversed Phase Vydac C18 (5 m icron, 4.6 x 250 
mm).
2.4.1 Solid Phase Peptide Synthesis
A num ber of steps are needed for the coupling of each am ino acid. 
Initially, a 30 second DMF w ash at 5 m L /m in. cleans the resin /p ep tid e  
followed by a 10 m in piperidine w ash at 5 m L /m in  to remove the FMOC 
from the N  term inus. After the piperidine wash, the re s in /p ep tid e  is 
again w ashed w ith  DMF for 12 m in (5 m L /m in.) to m ake sure all the 
piperidine has been rem oved so that no prem ature deprotection on the 
next amino acid coupled occurs. During this time, the next amino acid in 
line is being dissolved in a solution of DMF and 1-hydroxybenzotriazole 
(HOBT). The injection probe is w ashed w ith the DM F/HOBT solution for 
15 seconds at 10 m L /m in  The amino acid is then sent to the resin for a 1 
hour acylation period followed by an eight m in DMF w ash to rem ove 
excess am ino acid. The probe is again w ashed w ith  the DM F/HOBT 
solution for 1 m in at 10 m L /m in  The cycle is then repeated for each 
amino acid. However there is a modification to this protocol for the final 
residue. There is a second 10 min piperidine wash at 5 m L /m in  to remove
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the FMOC from the final amino acid. This final cycle ends w ith a 12 min 
DMF w ash at 5 m L/m in, a 15 m in DCM wash at 5 m L /m in , and a m anual 
w ash w ith m ethanol for 15 min to shrink the resin to facilitate cleavage of 
the peptide from the resin. The resin /pep tide is then filtered and dried. 
The peptide is cleaved from the resin using reagent B which is a solution 
of 8.8  mL of trifluoroacetic acid, 0.5 mL phenol, 0.5 mL water, and 0.2 mL 
triisopropylsilane. Argon is bubbled through reagent B to degas it. The 
pep tide/resin  is shaken under argon every thirty m in for a period of four 
hours. At the end of this time, the peptide has been removed from the 
resin and the m ixture is filtered to remove the resin. The peptides are 
purified by two different methods. In the first, the solution of peptide in 
the cleavage cocktail is dropped in equal volum es into six tubes of cold 
diethyl ether w ith 20 mL ether in each tube. A white precipitate of crude 
peptide forms in each tube. The tubes are centrifuged for 20 min at 7,000 
rpm . The ether is discarded and the peptide is w ashed w ith cold ether 
and centrifuged three additional times followed by drying under vacuum  
overnight to leave crude peptide. Several portions of the crude peptide 
w ere filtered on Sephadex G-15 (buffer 0.1M acetic acid, 4.5 x 55 cm 
column) in approxim ately 100 m g lots. The collected fractions w ere 
lyophilized for a period of two days. In the second method, the peptide in 
the cleavage cocktail is d ilu ted  to 150 mL w ith  20% acetic acid and 
extracted w ith 3x150 mL diethyl ether. The aqueous layer is lyophilized to 
yield crude peptide. Either of these methods is suitable to provide peptide 
for HPLC purification. Semipreparative RP-HPLC (gradient of 0.05% TFA 
in w ater and acetonitrile) was used to purify the crude peptides from 
either of these methods.
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2.4.2 M inim um  Inhibitory  Concentrations vs. Bacteria
The m inim um  inhib itory  concentration of these pep tides w ere 
com pared to that of natural peptides against Staphylococcus aureus (Gram 
positive), Pseudomonas aeruginosa, and Escherichia coli (Gram negative). 2:1 
serial dilutions of peptide were prepared from a 512 jig /m L  stock solution 
to allow a range of 256-2 |ig /m L  to be tested. Bacterial cultures were 
grow n to m id-log phase in nutrient broth and were standardized to a 0.5 
McFarland turbidity tube before dilution. To sterile wells were added 5 x 
1 0 ^ cells in 50 pL and an equal volum e of peptide. The m inim um  
inhibitory concentration is the lowest concentration that inhibits cell 
growth as evidenced by lack of turbidity.
2.4.3 Sublethal Concentrations vs. M ouse Embryo Cells
The sublethal dose of the peptide series (KLAKKLA)n was m easured 
against 3T3 and 3T12 cells. 2:1 serial dilutions of peptide were prepared to 
allow a range to be tested. To sterile wells were added 250 and 750 cells 
respectively. The supernatant was removed and 50 pL of fresh media was 
added. An equal volume of peptide solution was added. The cells were 
incubated for 30 min at 37 °C. After discarding the supernatant, 50 pL of 
Trypan blue stain was added to each well. The cells were fixed in a 4% 
paraform aldehyde solution. Light microscopy revealed cells w ith stained 
nuclei indicating cell death. Sublethal dose is defined as the highest 
concentration in which at least one cell nucleus is not stained indicating 
the presence of live cells.
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2.5 Conclusions
Contrary to the results of Lear et al, we have found that peptides of 
less than 20 residues still exhibit biological activity comparable to that of 
longer lytic peptides. CD measurem ents indicate that all of the peptides 
prepared, w ith the exception of the 7-mers, are helical in both TFE and in 
micelles. The 7-mers are not biologically active while the 14-mers retain 
high activity. Therefore, it appears that as long as the peptide is helical in 
either vesicles or m em brane mimetic solvents the peptides will be in an 
amphiphilic secondary structure and thus, biologically active. As opposed 
to naturally  occurring lytic peptides, the synthetic peptides exhibit 
virtually  identical activity against both Gram(+) and Gram(-) bacteria. 
The 21-mers are also highly active against mammalian cells. On the other 
hand the 14-mers show very little activity against mammalian cells.
CHAPTER THREE: SOLID-PHASE PEPTIDE SYNTHESIS
3.1 Introduction
All of the peptides prepared w ith the exception of the 7-mers exhibit 
antimicrobial activity. The highly repetitive nature of the sequences make 
them  viable targets for solution phase synthesis. Since the 14-mer 
peptides have low lytic activity against healthy mouse embryo (3T3) cells 
as well as high antim icrobial activity, we have chosen one of these 
peptides as our target for solution phase synthesis.
Linear synthesis of a 14-mer peptide via solid-phase peptide synthesis 
w ould involve 27 steps including couplings and deprotections. Solution- 
phase synthesis using a convergent approach w ould greatly reduce the 
total num ber of steps necessary to obtain a 14-mer. Also in solution-phase 
synthesis larger amounts of peptides can be prepared than in solid-phase 
peptide synthesis. O ur solid-phase syntheses have been perform ed on a 
0.2 mmol scale whereas the solution phase synthesis is only restricted by 
the am ount of starting material available.
In linear synthesis, molecules are assembled one piece at a time. In 
convergent synthesis the target molecule is assembled from fragments. 
The fragments are composed of individual pieces of the whole. (Figure 
3.1) H igher overall yields can be obtained by using convergent synthesis. 
For example, if each step in the linear synthesis in figure 3.1 gave a 90% 
yield, five steps w ould give an overall yield of 59%. The five steps in the 
convergent synthesis w ould give an overall yield of 73% if each step was 
also 90%. Thus, the final yields show the advantage of convergent
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synthesis. Even though both routes require five steps, the linear synthesis 
requires larger and larger molecules. The convergent synthesis on the 
other hand involves the coupling of smaller fragments to lead to the same 
product.
Linear Synthesis
ABCDEF
t
ABCDE + F
t
ABCD + E
t
ABC + D
t
AB + C
t
Convergent Synthesis 
ABCDEF
t
ABC + DEF 
At
AB + C DE + F
t t
A + B D + E
A + B
Figure 3.1 Linear Versus Convergent Synthesis
The use of a convergent approach in solution phase synthesis can be 
problematic. During the synthesis, the carboxy term inus is activated by 
converting the OH of the acid to a good leaving group. By activating the 
carboxy term inus undesired side reactions may result. One of these is
racem ization w hich is the loss of optical integrity at a chiral center. 
Racemization can occur through a five m embered interm ediate called an 
oxazolone formed by an intermolecular cyclization (Figure 3.2).
R
O
oxazolone
Figure 3.2 Oxazolone Formation
Oxazolones are themselves reactive molecules that will react w ith the 
am ine term inus fragment to yield the desired peptide (Figure 3.3).
n :
NHR'
'NH2
N H
^ r N
o
NHR'
H R
Figure 3.3 Peptide Formation from Oxazolones
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H ow ever, the oxazolone is subject to racem ization u n d er m ild 
conditions. Base catalyzed deprotonation is particularly likely because a 
planar aromatic anion is produced. W hen the anion is protonated the oc-H 
can attach to either face leading to racemization49 (Figure 3.4).
Doubly stabilized 
aromatic anion
Figure 3.4 Racemization of the Oxazolone
Active esters are often used for peptide coupling. If the carboxylic acid 
is converted to ester w ith  a stable leaving group then couplings can 
proceed easily. The active ester used for our synthesis is the ester of the 
peptide w ith 1-hydroxybenzotriazole (HOBT). The HOBT ester is formed 
in situ during the coupling reaction by first reacting the carboxylic acid 
w ith dicyclohexylcarbodiimide (DCC). The reaction of the active ester of 
DCC and the peptide w ith HOBT produces the HOBT active ester. The 
HOBT ester provides cleaner couplings than the DCC ester alone w ith 
reduced racemization (Figure 3.5).
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I H +
^  9°Ar R >
R OH  C + H* r  /  |
vcncdb q
R' = cyclohexyl
°  R' L O j
I
DCC R’
«v A  -
NH NH
R "N H
OAr
R'
O
R NHR"
Jj + "OAr
O
•N o H O - N  N
ArOH = HOBT
Figure 3.5 HOBT Active Esters for Peptide Synthesis
Racemization can be reduced further by the use of a slightly different 
coupling reagent l-hydroxy-7-azabenzotriazole (HOAT). Reactivity of 
HOAT esters is greater than that of HOBT as well. This increased 
reactivity may be the result of neighboring group participation (Figure 
3.6). The increased reactivity is evident in the coupling of Aib residues. 
W ith HOBT these difficult couplings are incomplete after 24 hours while 
the HOAT reaction is quantitative. Racemization in fragm ent couplings
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are reduced to less than l-2%.50 We have used HOAT for the fragm ent 
coupling in the synthesis of the 14-mer.
O
•N ,  ■N 'N
)— l
II .N , 
R — C — O - N  ' N  
= \  /
o R ,N H '.......N ^2 % _ /
HOAT
Figure 3.6 HOAT Activated Ester
3.2 Results and Discussion
After determ ining that each of the 14-mers prepared via solid phase 
synthesis had  com parable biological activity, we had to decide w hich 
peptide to select for solution phase synthesis. Since the synthesis w ould 
be convergent and involve fragm ent couplings, the obvious candidate 
w ould be the glycine containing peptide to avoid racemization. However, 
the ultim ate synthetic target w ould be an Aib containing peptide. The 
coupling of Aib residues is difficult and to m ore closely resem ble this 
target we chose between the Ala containing peptides.
The formation of the peptide bond is a reaction between the carboxylic 
acid of one amino acid or peptide w ith the a-am ino group of another. For 
this reaction to take place cleanly, the reactants m ust be blocked from 
further reaction to form undesired peptides. Therefore, if the bond is to be 
form ed at the nitrogen of one residue, the carboxylic acid m ust be 
protected (i.e. as the m ethyl ester) to prevent grow th of the peptide
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backbone at this site. The a-am ino group can be protected as well in the 
case w here the carboxylic acid is the desired reaction site. To prevent 
nucleophilic reactions at the e-nitrogen of lysine leading to branched 
peptides, we have employed an orthogonal protection scheme. Here, the 
oc-amino group and the e-amino group are protected w ith groups that are 
cleavable under different conditions. We use the t-butyloxycarbonyl 
(BOC) protecting group at the a-nitrogen. This group is rem oved by 
treatm ent of the peptide w ith TFA. The e-nitrogen is protected w ith the 
b en zy lo x y carb o n y l g ro u p  (Z) w hich  is rem oved  by  cataly tic  
hydrogenation or H B r/acetic acid. The use of orthogonal protecting 
groups allows the synthesis to proceed w ithout the form ation of side 
products arising from peptide growth at the side chains. O rthogonality 
also allows for the preparation of fully protected peptides w here the side 
chains rem ain blocked so that additional chemistry may be perform ed at 
the N-terminus of the peptide.
3.2.1 Retrosynthetic Analysis
The A la co n ta in in g  14-m er sequences w e p re p a re d  w ere  
(LysLeuAlaLysLeuAlaLys)2 and (LysLeuAlaLysLysLeuAla)2 - To choose 
betw een these two sequences we planned the synthesis of each and 
determ ined which w ould be the easiest. Retrosynthetic analysis was used 
to  p la n  th e  p o ss ib le  sy n th eses . The re tro s y n th e s is  of 
(LysLeuAlaLysLeuAlaLys)2 is shown in Figure 3.7.
The deprotected (KLAKLAK)2 14-mer is p repared  from the fully 
protected 14-mer. Synthesis of the fully protected 14-mer consists of the
50
HcN 1CLAKL AKKLAKL AK-OMe
u
BOC-K(Z)LAK(Z)LAKi(Z)K(Z)LAK(Z)LAK(Z)-OMe
BOC-K(Z)LAK(Z)LAK(Z)-OH + H 3N +-K(Z)LAK(Z)LAK(Z)-OMe
BOC-K(Z)LAK(Z)LAK(Z)-OMe
BOC-K(Z)OH + H3N+ -LAK(Z)LAK(Z)-OMe
BOC-LAK(Z)LAK(Z)-OMe
BOC-LAK(Z)-OH + H3N +-LAK(Z)-OMe
BOC-LAK(Z)-OMe
n
BOC-L-OH + H 3N  +-AK(Z)-OMe
I
BOC-AK(Z)-OMe
BOC-A-OH + H jN  -K(Z)-OMe
Figure 3.7 Retrosynthetic Analysis of (KLAKLAK)2
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coupling of one heptad  deprotected at the C-term inus w ith  a heptad  
deprotected at the N-term inus. The two deprotected heptads are both 
derived from the same heptad. Saponification of the heptad leads to the 
free acid and  treatm ent of the hep tad  w ith  TFA yields the hep tad  
deprotected at the N -term inus. The fully protected heptad  in tu rn  is 
prepared from the coupling of the BOC-deprotected hexamer w ith  BOC- 
Lys(Z)-OH. The hexam er is synthesized by coupling tw o deprotected 
trimers. Coupling of H 3+N-Ala-Lys(Z)-OMe (prepared by deprotection of 
BOC-Ala-Lys-OMe) w ith BOC-Leu-OH yields the tripeptide. Finally, the 
dipeptide could be prepared from BOC-Ala-OH and H 3+N-Lys(Z)-OMe.
Synthesis of the (KLAKKLA)2 14-mer is sim ilar to the synthesis of 
(KLAKLAK)2  (Figure 3.8). The final step is still deprotection of a fully 
protected 14-mer prepared from the coupling of two heptads. However, 
the hep tads are prepared from a trim er and a tetram er rather than a 
hexam er and  a single residue. The trim er is deprotected to be the C- 
term inus fragm ent and m ore of the trim er is deprotected at the N- 
term inus to synthesize the tetramer. The trim er is prepared in a linear 
fashion as before. Ala and Leu are coupled, followed by the coupling of 
Lys at the dipeptides N-terminus.
A lthough both syntheses are the same length, we have chosen the 
(KLAKKLA)2 peptide to synthesize. Advantages of the second synthesis 
include: low er cost ,the first synthesis requires both C and N -protected 
lysine, bo th  are expensive com pounds to pu rchase  and  d ifficult 
com pounds to prepare, or lysine and the second synthesis only has less 
sterically hindered fragm ent couplings betw een Ala and Lys residues. 
Therefore we chose the easier of the two proposed synthetic pathways.
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3.2.214-mer and  D-14 m er Syntheses
We have synthesized the (KLAKKLA)2 14-mer using the previously 
described coupling m ethodology and concurrently w e have synthesized 
pep tides w ith  ^A la in all places w here racem ization can occur. This 
allowed us to determine if separation of the potential diastereomers is
B jN  +KLAKKL AKL AKKL A-OM e
U
BOC-K(Z)LAK(Z)K(Z)LAK(Z)LAK(Z)K(Z)LA-OMe 
BOC-K(Z)LAK(Z)K(Z)K(Z)LA-OH + H3N +-K(Z)LAK(Z)K(Z)LAK-OMe
\  s
BOC-K(Z)LAK(Z)K(Z)LAK-OMe
11
BOC-K(Z)LA-OH + H^-KCZJKCZJLA-OMe
11
BOC-K(Z)K(Z)LA-OMe
BOC-K(Z)-OH + H ,N +-K(Z)LA-OMe
BOC-K(Z)LA-OMe
BOC-K(Z)-OH + H3N + -LA-OMe
BOC-LA-OMe
BOC-L-OH + H^T+-A-OM e
Figure 3.8 Retrosynthetic Analysis of (KLAKKLA)2
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possible. Both the hep tad  and the 14-mer are synthesized by fragm ent 
couplings. Therefore, we have synthesized a heptad w ith a ^A la in the 
th ird  position and a 14-mer with a ^Ala in the seventh position.
The peptides were synthesized following a general procedure w ith a 
few modifications.51 Early peptide couplings to prepare small fragments 
w ere carried  in DCM as the solvent. H ow ever, larger fragm ents 
(tetram ers and larger) are not soluble in DCM alone. A dding DMF 
solubilizes the pep tide  and  the coupling can proceed u n d er these 
conditions. In DMF alone, racemization becomes a concern because the 
oxazolone forms m ore easily in polar conditions. Therefore, DMF w as 
used in conjunction w ith DCM as a co-solvent and the reaction initially 
proceeds at 0 °C to help prevent racem ization. Saponification of the 
peptide methyl esters is carried out in IN  NaOH in methyl alcohol for all 
peptides except the heptads. At this size, the peptide is no longer soluble 
in methanol. Therefore, alternate conditions were used. The heptad esters 
w ere saponified in 2N N aO H  in isopropyl alcohol.52 HOAT was only 
used in the final coupling to prepare the 14-mer, although the fragm ent 
coupling to prepare the heptad could undergo racemization as well. This 
decision was governed by the availability of HOAT. At the time of this 
w ork, HOAT was not yet available for purchase. Only small sam ples 
could be obtained. We therefore retained the HOAT for use in the the 
final coupling.
To prepare the ^heptad, a tripeptide containing ^Ala at the C-terminus 
w as coupled to a tetrapeptide with no ^Ala (Figure 3.9). By preparing the 
heptad w ith ^Ala at this site, we could determ ine if the heptad w ith and 
w ithout ^ Ala are separable by chromatography.
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BOC-K(Z)LdAK(Z)K(Z)LA-OMe
 ^ tv  
BOC-K(Z)LdA-OH + H3N+-K(Z)K(Z)LA-0Me
Figure 3.9 Synthesis of ^Ala Containing H eptad
The 14-mer w ith ^Ala w as prepared by coupling a heptad w ith ^Ala at 
the C-terminus w ith a heptad w ith no ^Ala. To prepare the heptad w ith
i
^A la at the C-term inus, a trim er w ith no dA la w as coupled w ith  a 
tetram er w ith no ^Ala and this peptide was saponified and coupled w ith a 
BOC deprotected heptad (Figure 3.10). Thin layer chrom atography and 
flash chrom atography on silica gel were used for the purification of the 
peptides.
BOC-K(Z)LAK(Z)K(Z)LdAK(Z)LAK(Z)K(Z)LA-OMe
> t
BOC-K(Z)LAK(Z)K(Z)LdA-OH + H ^ +-K(Z)LAK(Z)K(Z)LA-OMe 
Figure 3.10 Synthesis of ^Ala Containing 14-mer
The peptides were characterized by mainly two m ethods. MS was 
used to verify m olecular w eight and amino acid analysis w as used to 
verify amino acid composition .53 The amino acid analysis was carried out 
on the fully protected peptides. A sample of the peptide was hydrolized 
under vacuum  in 6N HC1 at 110 °C for 24h. The hydrolysis not only broke 
the peptide into its individual amino acid, it also removed the BOC and Z
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protecting groups as well. The resulting orange solutions were dessicated 
under vacuum  over NaOH. The orange color was not soluble w hen the 
residue was taken up  in the first sodium  buffer eluant. Ion-exchange 
chrom atography on a cation-exchange column separates the amino acids 
and allows the composition to be determined. For tetramer peptides and 
smaller, lH  NMR spectra are useful as well. Major peaks in the NMR 
spectra, those of the p ro tecting  groups, w ere used  for structu re  
elucidation. By comparing the integration of these peaks, the composition 
can be determined. NMR data for the dipeptide through the tetrapeptide 
is provided in Appendix B.
3.3 Experimental
G eneral M ethods: NMR were m easured at 200 MHz on a Bruker
AC 200 spectrometer. MS were perform ed on an Applied Biosystems 
Bioion 20 plasm a desorption mass spectrometer. Amino acid analyses 
were perform ed by the ninhydrin m ethod on a Pickering Laboratories 
sodium  cation exchange column.
3.3.1 Synthesis of BOC-Leu-Ala-OMe (1).
HCl-H-Ala-OMe (5.00 g, 35.8 mmol) in 150 mL DCM at 0 °C was 
neutralized w ith TEA (3.62 g, 35.8 mmol). A solution of BOC-Leu-OH 
(8.28 g, 35.8 mmol) in 150 mL DCM was added followed by the addition of 
solid HOBT (4.84 g, 35.8 mmol). The mixture was stirred in an ice bath for 
5 min. DCC (7.39 g, 35.8 mmol) in 50 mL DCM was added and the
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mixture was stirred for 4 hours at 0 °C and at room tem perature overnight. 
DCU was removed and the filtrate wasconcentrated in vacuo. The residue 
w as taken up in ethyl acetate and w ashed w ith IN  HC1 (2x), saturated 
NaHCC>3 (2x), and brine (2x). The organic layer was dried over M gS04 
and evaporated to yield crude 1. Pure 1 was precipitated from CHCI3 
w ith ether (10.1 g, 31.9 mmol, 89.1%), *H NMR (200 MHz, CDCI3 ), 1.49 (s, 
9H), 3.75 (s, 3 H ),.
3.3.2 Synthesis of CF3COOH H-Leu-Ala-OMe (2).
BOC-Leu-Ala-OMe (10.0 g, 31.6 mmol) was dissolved in 0 °C TFA (350 
mL) and stirred for 30 min. The TFA was rem oved in vacuo and the 
residue was evaporated three times from MeOH. The resulting oil was 
precipitated from ether to afford 2 (8.40 g, 24.2 mmol, 76.7%), m.p. 143-145 
°C.
3.3.3 Synthesis of BOC-Lys(Z)-Leu-Ala-OMe (3).
CF3COOH-H-Leu-Ala-OMe (9.22 g, 26.6 mmol) w as dissolved in 50 
mL DCM /DM F, cooled to 0 °C, and neutralized w ith TEA (2.7 g, 26.6 
mmol). A solution of BOC-Lys(Z)-OH (10.1 g, 26.6 mmol) in 50 mL DCM 
w as added followed by the addition of solid HOBT (3.6 g, 26.6 mmol). 
The mixture was stirred in an ice bath for 5 min. DCC (5.49 g, 26.6 mmol) 
in 25 mL DCM was added and the mixture was stirred for 4 hours at 0 °C 
and at room tem perature overnight. DCU was removed and the filtrate 
w as concentrated in vacuo. The residue was taken up in DCM and
57
w ashed w ith IN  HC1 (2x), saturated NaHCC>3 (2x), and saturated sodium  
ch loride (2x). The organic layer w as d ried  over M gS04 and 
evaporated.The crude product was precipitated from CHCI3 w ith ether to 
yield a w hite solid 3 (13.5 g, 23.3 mmol, 87.7%), m.p. 116-117 °C, NMR 
(200 MHz, CDCI3 ), 1.43 (s, 9H), 3.71 (s, 3H), 5.10 (s, 2H), 7.31-7.36 (m, 5H), 
M+ 578.
3.3.4 Synthesis of CF3COOH-H-Lys(Z)-Leu-Ala-OMe (4).
BOC-Lys(Z)-Leu-Ala-OMe (5.0 g, 8.6 mmol) was dissolved in 0 °C TFA 
(100 mL) and stirred for 30 min. The TFA was removed in vacuo and the 
residue evaporated  th ree tim es from M eOH. A w hite  solid  w as 
precipitated from the resulting oil from the addition of chloroform /ether 
to afford 4 (8.40 g, 24.2 mmol, 75.0%), m.p. 145-147 °C.
3.3.5 Synthesis of BOC-Lys(Z)-Leu-Ala-OH (5).
BOC-Lys(Z)-Leu-Ala-OMe (4.00 g, 6.76 mmol) was dissolved in 40 mL 
of MeOH followed by addition of 10 mL of 1 N  NaOH. The reaction 
m ixture was allowed to stir overnight at room tem perature. The MeOH 
was rem oved in vacuo and the rem aining aqueous m ixture was diluted 
w ith 100 mL water. The aqueous solution was w ashed w ith ethyl acetate 
and acidified to ~ pH  3 w ith potassium  bisulfate. The acidified solution 
was extracted three times w ith ethyl acetate. The combined organic layers 
w ere w ashed w ith water, dried over M gS04, and evaporated to yield 5 
(3.62 g, 6.42 mmol, 95.0%).
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3.3.6 Synthesis of BOC-Lys(Z)-Lys(Z)-Leu-Ala-QMe (6).
CF3COOH-H-Lys(Z)-Leu-Ala-OMe (3.44 g, 5.80 mmol) w as dissolved 
in  50 mL of DCM /DM F, cooled to 0 °C, and neutralized w ith TEA (0.59 g,
5.8 mmol). A solution of BOC-Lys(Z)-OH (2.21 g, 5.8 mmol) in 50 mL of 
DCM /D M F w as added followed by the addition of solid HOBT (.784 g,
5.8 mmol). The m ixture w as stirred in an ice bath for 5 min. DCC (5.49 g,
26.6 mmol) in 25 mL DCM w as added and the m ixture w as stirred for 4 
hours at 0 °C and at room tem perature overnight. DCU was rem oved and 
the filtrate was concentrated in vacuo. The residue was taken up  in DCM. 
The solution was w ashed w ith IN  HC1 (2x), saturated NaHCC>3 (2x), and 
saturated sodium  chloride (2x). The organic layer was dried over MgSC>4 
and  evaporated . The rem ain ing  residue w as p u rified  by flash 
chrom atography on silica gel using 9:1 CFICl3 :MeOFl as the eluant.. 
Evaporation of the solvent yields 6 (3.52 g, 4.2 mmol, 72.1%), m.p. 152-155 
°C, ! h  NMR (200 MHz, CDCI3), 1.42 (s, 9H), 3.70 (s, 3H), 5.09 (s, 4H), 7.26- 
7.33 (m, 10H), M+ 842.
3.3.7 Synthesis of CF3COOH*H-Lys(Z)-Lys(Z)-Leu-Ala-OMe (7).
BOC-Lys(Z)-Lys(Z)-Leu~Ala-OMe (2.77 g, 3.29 mmol) was dissolved in 
0 °C TFA (40 mL) and stirred for 30 min. The TFA was rem oved in vacuo 
and the residue evaporated three times from MeOH. A w hite solid was 
precipitated from the resulting oil from the addition of ether to afford 7 
(2.30 g, 2.69 mmol, 82.0%), m.p. 175-177 °C.
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3.3.8 Synthesis of BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-QMe
(8).
CF3COOH-H-Lys(Z)-Lys(Z)-Leu-Ala-OMe (2.67 g, 3.12 mmol) was 
dissolved in 30 mL of DCM /DM F, cooled to 0 °C, and neutralized with 
TEA (0.316 g, 3.12 mmol). A solution of BOC-Lys(Z)-Leu-Ala-OH (1.76 g, 
3.12 mmol) in 30 mL of DCM /DM F was added followed by the addition 
of solid FIOBT (0.422 g, 3.12 mmol). The mixture was stirred in an ice bath 
for 5 min. DCC (0.644 g, 26.6 mmol) in 25 mL DCM was added and the 
mixture was stirred for 4 hours at 0 °C and at room tem perature overnight. 
DCU w as rem oved and the filtrate was concentrated in vacuo. The 
residue was taken up in DCM and w ashed w ith IN  F1C1 (2x), saturated 
NaHCOs (2x) (after the basic extraction an em ulsion formed which was 
broken up by filtration), and saturated sodium chloride (2x). The organic 
layer was dried over M gS04 and evaporated. The peptide was purified 
by flash chrom atography on silica gel using 9:1 CHCl3 :MeOH to separate 
the epimers. (2.61 g, 2.05 mmol, 73.0%) m.p. 215-217 °C, M+ 1288.
3.3.9 Synthesis of CF3COOH*H-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu- 
Ala-OMe (9).
BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0.75 g, 0.588 mmol) 
was dissolved in 0 °C TFA (7.0 mL) and stirred for 30 min. The TFA was 
rem oved in vacuo and the residue evaporated three times from MeOH. 
Asolid was precipitated from the resulting oil from the addition of ether to 
afford 9 which was used w ithout further purification (0.72 g, 0.558 mmol,
95.0 %), m.p. 179-181 °C.
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3.3.10 Synthesis of BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-QH 
(10).
To BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0.72 g, 0.565 
mmol) was added 25 mL of isopropyl alcohol and 5 mL of 2N NaOH. The 
mixture dissolved upon slight heating and stirring continued overnight at 
room tem perature. The m ixture was diluted w ith 30 mL w ater and the 
isopropyl alcohol was removed in vacuo. The mixture was acidified to ~ 
pH  3 w ith  20% citric acid at 4 °C for 2 hours. The w hite solid was 
collected and  dried u nder vacuum  over P2 O 5 . The solid w as used 
w ithout any further purification (0.620 g, 0.491 mmol, 87.0 %).
3.3.11 S yn thesis  of Boc-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala- 
Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (11).
CF3COOH-H-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0.50 g, 
0.388 mmol) was dissolved in 15 mL of DCM /DM F, cooled to 0 °C, and 
neutralized w ith TEA (0.040 g, 0.0388 mmol). A solution of BOC-Lys(Z)- 
Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OH (0.489 g, 0.388 mmol) in 15 mL of 
DCM /DM F was added followed by the addition of solid HOAT (0.053 g, 
0.388 mmol). The mixture was stirred in an ice bath for 5 min. DCC (0.800 
g, 0.388 mmol) was added and the mixture was stirred for 4 hours at 0 °C 
and at room tem perature overnight. DCU was removed and the filtrate 
concentrated in vacuo. The residue was taken up in DCM and washed 
w ith IN  HC1. The organic layer was dried over MgSC>4 and evaporated. 
The peptide was purified by flash chrom atography on silica gel using 9:1 
C H C l 3 :MeOH to separate  the epim er(0.492 g,0.202 m m ol, 52%) 
decomposes 235 °C, M+ 2535.
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3.3.12 Synthesis of BOC-Leu-^Ala-OMe (12).
HCl-^Ala-OMe (3.00 g, 21.5 mmol) was dissolved in 28 mL of DCM, 
cooled to 0 °C and neutralized w ith TEA (2.17 g, 21.5 mmol). HOBT (2.90 
g, 21.5 mmol) and Boc -Leu-OH (4.96 g, 21.5 mmol) were added and the 
m ixture was stirred in an ice bath for 5 min. DCC (4.43 g, 21.5 mmol) was 
added and the reaction was stirred overnight. DCU was rem oved from 
the reaction m ixture by filtration and the filtrate w as evaporated to a 
yellow oil. The residue was dissolved in 50 mL ethyl acetate and w ashed 
w ith  water, 1 N  HC1, saturated N aH C 03, and brine. The organic layer 
w as dried over MgSC>4 and evaporated to yield (12 ) (2.45 g, 7.74 mmol, 
36.1%) m.p. 87-89 °C, XH NMR (200 MHz, CDCI3 ), 1.44 (s, 9H), 3.67 (s, 
3H), M+ 317.
3.3.13 Synthesis of CFsCOOH'H-Leu-^Ala-OM e (13).
BOC-Leu-^Ala-OMe (2.00 g, 6.32 mmol) was dissolved in 63.0 mL of 
TFA at 0 °C and stirred for 30 min. The TFA was removed in vacuo and 
the residue evaporated three times from MeOH. The resulting oil was 
precipitated from ether to afford 13 which was used directly.
3.3.14 Synthesis of BOC-Lys(Z)-Leu-^Ala-OMe (14).
CF3COOH-H-Leu-^Ala-OM e (2.00 g, 6.06 mmol) was dissolved in 45 
mL of DCM, cooled to 0 °C and neutralized with TEA (0.61 g, 6.06 mmol). 
HOBT (0.82 g, 6.06 mmol) and Boc -Lys(Z)-OH (2.31 g, 6.06 mmol) w ere
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added and the m ixture was stirred in an ice bath for 5 min. DCC (1.25 g,
6.06 mmol) was added and the reaction was stirred overnight. DCU was 
rem oved from  the reaction m ixture by filtration and the filtrate w as 
evaporated to a yellow oil. The residue was dissolved in 50 mL DCM and 
w ashed w ith water, 1 N  HC1, saturated N aH C03, and brine. The organic 
layer w as d ried  over MgSC>4 and evaporated . The residue  w as 
precipitated from CHCI3 w ith ether to yield 14 (2.62 g, 4.53 mmol, 74.8%) 
m.p. 126-128 °C, *H NMR (200 MHz, CDCI3), 1.36 (s, 9H), 3.61 (s, 3H), 5.03 
(s, 2H), 7.19-7.28 (m, 5H), M+ 580.
3.3.15 Synthesis of CF3COOH H-Lys(Z)-Leu-<iAla-OMe (15).
BOC-Lys(Z)-Leu-^Ala-OMe (1.16 g,2.00 mmol) was dissolved in 20.0 
mL of TFA at 0 °C and stirred for 30 min. The TFA was removed in vacuo 
and the residue evaporated three times from MeOH. The resulting oil was 
precip ita ted  from  ether to afford 1 5 . 15 w as used w ithou t further 
purification.
3.3.16 Synthesis of BOC-Lys(Z)-Lys(Z)-Leu-^Ala-OMe (16).
CF3COOH-H-Lys(Z)-Leu-dAla-OMe (1.18 g, 2.00 mmol) was dissolved 
in 15 mL of DCM /DM F, cooled to 0 °C and neutralized w ith TEA (0.202 g,
2.00 mmol). HOBT (0.270 g, 2.00 mmol) and Boc-Lys(Z)-OH (0.761 g, 2.00 
mmol) w ere added and the mixture was stirred in an ice bath for 5 min. 
DCC (0.413 g, 2.00 mmol) w as added and the reaction w as stirred  
overnight. DCU was removed from the reaction mixture by filtration and
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the filtrate w as evaporated to a yellow oil. The residue w as dissolved in 
50 mL DCM and w ashed w ith water, 1 N HC1, saturated N aH C0 3 , and 
brine. The organic layer was dried over M gS04 and evaporated. The 
pep tide was purified by flash chrom atography on silica gel using 9:1 
CHCl3 :MeOH to yield 16 (0.770 g, 0.92 mmol, 45.8%) m.p. 171-173 °C, ! h  
NMR (200 M Hz, CDCI3 ), 1.37 (s, 9H), 3.64 (s, 3H), 5.05 (s, 4H), 7.34 (s, 
10H), M+ 842.
3.3.17 Synthesis of CF3COOHH-Lys(Z)-Lys(Z)-Leu-d Ala-OM e (17).
BOC-Lys(Z)-Lys(Z)-Leu-d Ala-OMe (2.00 g, 2.38 mmol) w as dissolved 
in 24.0 mL of TFA at 0 °C and stirred for 30 min. The TFA was removed in 
vacuo and the residue evaporated three times from MeOH. The resulting 
oil was precipitated from ether to afford 17. 17 was used w ithout further 
purification.
3.3.18 Synthesis of BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-d Ala- 
OM e (18).
CF3COOH-H-Lys(Z)-Lys(Z)-Leu-dAla-OMe (0.600 g, 0.702 mmol) was 
dissolved in 7 mL of DCM/DM F, cooled to 0 °C and neutralized w ith TEA 
(0.071 g, 0.702 mmol). HOBT (0.095 g, 0.702 mmol) and Boc-Lys(Z)-Leu- 
Ala-OH (0.396 g, 0.702 mmol) were added and the m ixture was stirred in 
an ice bath  for 5 min. DCC (0.145 g, 0.702 mmol) was added  and the 
reaction w as stirred overnight. DCU was rem oved from  the reaction 
m ixture by filtration and the filtrate was evaporated to a yellow oil. The
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residue w as dissolved in 50 mL CHCI3 and w ashed w ith water, 1 N HC1, 
saturated N aH C 03, and brine. The organic layer was dried over MgSC>4 
and evaporated to yield 18 which was purified by flash chrom atography 
on silica gel using 9:1 CHCl3 :MeOH (0.600 g, 0.470 mmol, 67.0%) m.p. 213- 
215 °C, M+ 1288.
3.3.19 Synthesis of BOC-Lys(Z)-Leu-dAla-OH (19).
BOC-Lys(Z)-Leu-^Ala-OMe (0.578 g,1.00 mmol) was dissolved in 5 mL 
of M eOH followed by addition of 1.5 mL of IN  NaOH. The reaction 
m ixture was allowed to stir overnight. The MeOH was removed in vacuo 
and the rem aining aqueous m ixture was diluted w ith 50 mL water. The 
aqueous solution was w ashed w ith ethyl acetate and acidified to ~ pH  3 
w ith potassium  bisulfate and extracted three times w ith ethyl acetate. The 
combined organic layers w ere washed w ith water, dried over MgS04, and 
evaporated to yield 19 (0.535 g, 0.95 mmol, 95.0%).
3.3.20 Synthesis of BOC-Lys(Z)-Leu-^Ala-Lys(Z)-Lys(Z)-Leu-Ala- 
OM e (20).
CF3COOH-H-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0..855 g, 1.00 mmol) was 
dissolved in 10 mL of DCM /DM F, cooled to 0 °C and neutralized w ith 
TEA (0.101 g, 1.00 mmol). HOBT (0.135 g, 1.00 mmol) and BOC-Lyz(Z)- 
Leu-^A la-O H  (0.564 g, 1.00 mmol) w ere added  and the m ixture was 
stirred in an ice bath for 5 min. DCC (0.206 g, 1.00 mmol) was added and 
the reaction was stirred overnight. DCU was rem oved from the reaction
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m ixture by filtration and the filtrate was evaporated to a yellow oil. The 
residue w as dissolved in 25 mL DCM and w ashed w ith water, 1 N HC1, 
saturated N aH C 03, and brine. The organic layer was dried over MgSC>4 
and evaporated. The peptide was purified by flash chrom atography on 
silica gel using 9:1 CHCl3 :MeOH to yield 20 (0.260 g, 0.204 mmol, 20.4%) 
m p 174-176 °C, M+ 1288.
3.3.21 Synthesis of BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-dAla-OH 
(21).
To BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0.72 g, 0.565 
mmol) was added 10 mL of isopropyl alcohol and 1.8 mL of 2N NaOH. 
The m ixture stirred overnight at room tem perature. The m ixture was 
diluted w ith 10 mL w ater and the isopropyl alcohol rem oved in vacuo. 
The m ixture was acidified to ~ pH  3 w ith 20% citric acid at 4 °C for 2 
hours. The white solid was collected and dried under vacuum  over P2O5 . 
The solid was used w ithout any further purification.
3.3.22 Synthesis of BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-d Ala- 
Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (22).
CF3COOH-H-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-Ala-OMe (0.102 g, 
0.079 mmol) was dissolved in 5 mL of DCM /DM F, cooled to 0 °C and 
neutralized w ith TEA (0.008 g, 0.079 mmol). HOBT (0.011 g, 0.079 mmol) 
and  BOC-Lys(Z)-Leu-Ala-Lys(Z)-Lys(Z)-Leu-d Ala-OH (0.100 g, 0.079 
mmol) w ere added and the mixture was stirred in an ice bath for 5 min. 
DCC (0.016 g, 0.079 mmol) was added and the reaction w as stirred 
overnight. DCU was removed from the reaction mixture by filtration and
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the filtrate was evaporated to an oil. The residue was dissolved in 14 mL 
CHCI3 and w ashed w ith water, 1 N HC1, saturated N aH C03, and brine. 
The organic layer was dried over M gS04 and evaporated. The peptide 
w as p u rified  by flash ch rom atography  on silica gel u sing  9:1 
CHCl3 :MeOH to yield 22 (2.45 g, 7.74 mmol, 36.1%) m.p. 162-165 °C, M+ 
2463.
3.3.23 Am ino Acid A nalysis
Peptide samples and 6N  HC1 (0.1% phenol) were frozen in pyrex tubes 
and sealed under vacuum. The peptides were hydrolyzed at 110 °C for 24 
h. The solutions turned orange during the hydrolysis. The hydrolyzed 
peptides w ere dessicated under vacuum  over NaOH to remove the HC1. 
The residue w as taken up  in the eluant and  the orange color d id  not 
dissolve. A 3 x 250 mm, 10 micron sodium  cation-exchange colum n at 45 
°C w as used for the am ino acid analysis. An eluant system of sodium  
buffers was supplied in a gradient from pH  3.38-7.40 at a flow rate of 0.25 
m L/m in. The amino acids were derivitized by post-column reaction w ith 
ninhydrin at 130 °C and detected at 570 nm.
3.4 Conclusions
Solution phase synthesis led to the desired 14-mer. By using  a 
convergent approach for the solution phase synthesis, we have prepared 
the fully protected peptide in 11 steps. Linear solution phase synthesis 
w ould require 27 steps. Co-spotting of the heptad and the D-heptad using
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TLC show ed sep ara tio n  of the  h ep tad  d iastereom ers. C olum n 
chrom atography also allowed the diastereom ers to be separated. Co- 
spotting of the 14-mers also showed two spots. HOAT was used in the 
final coupling to yield the 14-mer and only one spot was seen indicating 
only one racemer was obtained. Future w ork will include the synthesis of 
the 14-mer and 21-mer glycine containing peptides and the preparation of 
calixarene templates of various sizes for the synthesis of TASP molecules.
PART II The Synthesis of Benz[/Jindene and 
2,3,6,7-Dibenzfluorenone for the Preparation of Novel 
Metallocenes 
CHAPTER FOUR: BENZ[/JNDENE AND 2,3,6,7- 
DIBENZFLUORENONE
4.1 Introduction
The objectives of this w ork have been the synthesis of ligands to be 
used for the preparation of new  cylcopentadienyl-m etal complexes and 
the synthesis of am phipathic peptides showing antibacterial activity. The 
cyclopentadienyl derivatives that have been p repared  are the know n 
com pounds benz[/]indene and 2,3,6,7-dibenzfluorenone. Each of which 
has been synthesized via new  a pathway.,
O ur interest in both benzj/Jindene and 2,3,6,7-dibenzfluorenone results 
from  the possible anthracene-like reactivity expected from  the T|5- 
cyclopentadienyl-metal complexes. Also, benz[/]indene has been show n 
to be an alternative to fluorene in the preparation of FMOC-type amino 
acid protecting groups for peptide synthesis .54 The previously reported 
syn theses of these com pounds are long and  difficu lt processes. 
Benz[/]indene was synthesized by Carpino in eight steps using traditional 
organic chem istry  u tiliz ing  a Friedel-C raft cyclization .55 2,3,6,7- 
Dibenzfluorenone was prepared by M artin by adding lead acetate to an 
aqueous so lu tion  of sodium  2,2 '-dinapthyl-3,3 '-dicarboxylate. The 
resulting lead salt was pyrolyzed to give 2,3,6,7-dibenzfluorenone in an
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8% overall y ield .56 Therefore, we set out to prepare these com pounds by 
m ore attractive methods.
4.2 Results and  Discussion
4.2.1 Benz[/Iindene
The desired compounds were prepared in fewer steps and w ith greater 
overall yields than reported literature m ethods. Two different m ethods 
w ere  em ployed  to syn thesize  benz[f]indene. In  the first, 1,3- 
cyclopentadiene, excess sodium  hydride, and a,a,a'-tribromo-o-xylene 
react to give benz[/]indene in a 25% yield (Figure 4.1). O verall, the 
synthesis is tw o steps because the a,a,oc'-tribrom o-o-xylene is not 
commercially available and m ust be prepared by brom inating xylene .57 
a,a,a'-Tribrom o-o-xylene is a severe lachrymator and to avoid the use of 
this com pound we explored an alternate synthesis.
In this reaction, N aH  first depro tonates cyclopentadiene. The 
cyclopentadiene anion then acts as a nucleophile and attacks either the 
m onobrom inated or the dibrom inated carbon. The m onobrom inated 
carbon is less sterically hindered and the dibrom inated carbon is m ore 
electron deficient. A ttack at either site leads to the sam e product.
CHBr. NaH,THF
Figure 4.1 First Synthesis of Benz[f]indene
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Following a pro ton  shift, the second carbon is attacked. A th ird  proton 
shift followed by elimination yields a proton shift isomer of benz[/]indene. 
A final proton shift then leads to the desired molecule as show n in Figure 
4.2.
1) p ro ton  shift
2) N aH
Br
1) p ro ton  shift
p ro to n  shift
\  p ro ton  shift
Figure 4.2 Proposed Mechanism for Benz[/]indene Formation
The second m ethod is a reaction betw een a,a,a',a'-tetrabrom o-o- 
xylene, 2 -cyclopen ten-l-one, and excess sod ium  iod ide  to form  
benz[/]indan-l-one in a 57% yield. Reduction of benz[/]indan-l-one (87% 
yield) and dehydration of the resulting benz(/]indan-l-ol gives the target 
molecule in a 40% overall yield (Figure 4.3).58
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O Q
CHBr2
HBr2
+
NaI,DMF, 
80 °C, 18 h
LAH, THF 
25 °C, 2 h
OH
10% H2S 0 4 
100 °C,24 h
Figure 4.3 Second Synthesis of Benz[/]indene
4.2.2 Dibenzfluorenone
The first step in the p reparation  of 2,3,6,7-dibenzfluorenone is the 
synthesis of benz[/]indan-l-one. Benz[/]indan-l-one is brom inated w ith 
NBS. NMR showed evidence of brom ination in both the two and three 
positions. Separation of these two isomers was difficult and since both 
w ould lead to the same product by elimination, we used the m ixture of 
isom ers. E lim ination w ith  trie thy lam ine gave benz[/]inden-l-one. 
Reaction of benz[f]inden-l-one, a,a,a',a '-tetrabrom o-o-xylene, and excess 
sodium  iodide produces 2,3,6,7-dibenzfluorenone in a 16% overall yield 
(Figure 4.4).
R eaction  of a ,a ,a ',a '-te trab rom o-o -xy lene  w ith  sod ium  iodide 
produces dibrom oquinodim ethane via a nucleophilic attack of the sodium  
iodide on a brom ide followed by 1,4-elimination of a second bromide. The 
resulting quinodim ethane is a very active diene for a Diels-Alder reaction 
because cyclization reestablishes arom aticity. E lim ination of tw o 
molecules of HBr leads to a 2,3 substituted naphthalene (Figure 4.5).59
Thus, reaction of a,a,a',a '-tetrabrom o-o-xylene and sodium  iodide w ith
cyclopenten-l-one as a dienophile leads to benz[/]indene. Similarly, using
benz[/]inden-l-one as a dienophile yields dibenzfluorenone.
NBS,CC14 
Benzoyl peroxide
N(Et)3,CCl4
25 °C +
CHBr
O
NaI,DMF, 
80 ° c ,  18 h
Figure 4.4 Synthesis of Dibenzfluorenone
Br x N  
I f  \ 
CH -B r  I'
C H -B r
Br
CH
CH
YH X
X
X
-2 HBr
Figure 4.5 Formation and Diels-Alder of Dibromoquinodimethane
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All attem pts to reduce 2,3,6,7-dibenzfluorenone failed. Wolff-Kishner 
reduction  and hydrogenolysis using W-7 Raney-N ickel60 w ere both  
attem pted and showed incomplete reaction after reacting for extended 
periods.
4.2.3 A ttem pted M etal Complexations
A ttem pts to  p rep are  m etal com plexes of b en z[/]in d en e  w ere  
unsuccessful. Efforts w ere m ade to prepare iron(II) and ruthenium (II) 
complexes. The attem pted syntheses of bis(Ti^-benz[/]indenyl)iron(II) 
gave no evidence of com plexation. O nly sm all am ounts of the 
u n s y m m e t r i c a l  r u t h e n o c e n e  (r| 5 - b e n  z [/]indenyl)(r|5- 
pentamethylcyclopentadienyl)ruthenium(II) were obtained. In both cases 
the benz[/]indene was depro tonated  w ith  m ethyllith ium . For the 
attem pted synthesis of the iron complex FeCl2 :2THF was added and for 
the ruthenium  complex Cp*RuCl2 oligom er w as ad d ed 61. Difficulty 
preparing  iron complexes of similar benz-annulated indenes has been 
previously observed.
Figure 4.6 Attempted Preparation of Bis(r|5-benz If] indenyl) Iron(II)
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Cp RuC12 
C H 3Li
Figure 4.7 Synthesis of (r|5-Benz[/]indenyl)(r|5-Cp*) Ruthenium(II)
Figures 4.6 and 4.7 show  the attem pted syntheses of the iron and 
ruthenium  metal complexes.
4.3 Experimental
G eneral M ethods: NMR w ere obtained on a Bruker AC 200
spectrom eter at 200 MHz. IR spectra were m easured on a Perkin-Elmer 
1760X FTIR. G C /M S w ere perform ed on a H ew lett Packard HP5995. 
Tetrahydrofuran was distilled from potassium under argon.
4.3.1 Synthesis of Benz[/|indene.
Freshly cracked 1,3-cyclopentadiene (1.93 g, 29.2 mmol) w as added 
slowly to excess sodium  hydride (2.10 g, 87.5 mmol) in 200 mL of THF at 
room  tem perature. The gray suspension was cooled to 0°C and a solution 
of a,a,a'-tribrom o-o-xylene (5.00 g, 14.6 mmol) in 100 mL THF was added
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while m aintaining the tem perature at 0°C. The reaction turned green over 
several m in and then purple after several hours w hen w arm ed to room 
tem perature. After 60 h  the reaction was quenched w ith w ater, the 
organic layer w as dried, solvent was rem oved under reduced pressure 
and the residue sublim ed to yield benz[/]indene in a 25 % yield (m.p. of 
162-163 °C, lit m.p. 163-164 °C, NMR (200 MHz, CDCI3 ), 3.54-3.55 (d, 
2H), 6.63-6.67 (m, 1H), 6.97-7.00 (m, 1H), 7.29-7.87 (m, 6H).
4.3.2 Synthesis of Benz[/]indan-l-one.
a,a,a',a'-Tetrabrom o-o-xylene (30.0 g, 71.1 mmol) and 2-cyclopenten-l- 
one 5.83 g, 71.1 mmol) w ere dissolved in 270 mL DMF. Sodium iodide 
(69.7 g, 465 mmol) was added, the m ixture was heated to 80°C 62, and 
stirred overnight. The resulting dark red solution was poured into an 
ice/w ater mixture, decolorized by adding sodium  bisulfite, and a yellow 
precipitate formed. The solid was collected and recrystallized from 95% 
ethanol to give benz[f]indan-l-one in a 57% yield; m.p. 144-145 °C; lit m.p. 
140-141 °C; *H NMR (200 MHz, CDCI3 ) 2.77-2.83 (t, 2H), 3.29-3.35 (t, 2H), 
7.45-8.32 (m, 6H).
4.3.3 Second Synthesis of Benz[/]indene.
To a suspension of lithium alum inum hydride (4.12 g, 11.0 mmol) in 25 
mL dry  THF was added benz(/]indan-l-one (5.00 g, 27.4 mmol) dissolved 
in 100 mL dry THF dropwise. After final addition, the mixture was stirred 
for two hours at room tem perature. The reaction was quenched w ith 10
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mL water, followed by 30 mL 10% of sulfuric acid. The m ixture w as 
extracted w ith 3x100 mL portions ethyl ether, the combined organic layers 
washed w ith 3x75 mL portions water, dried w ith m agnesium  sulfate, and 
evaporated under reduced pressure to yield a light yellow solid. The solid 
w as found to be benz[f]indan-l-ol in a 87% yield and w as suitably pure 
for use in the next step. Benz[f]indan-l-ol (4.46 g, 24.2 mmol) w as 
dehydrated by refluxing in 130 mL of 10% sulfuric acid for one day. After 
cooling to room tem perature, the mixture was extracted w ith 3x80 mL of a 
1:2 benzene:hexane solution. The combined organic layers were w ashed 
w ith  3x50 mL of water, dried w ith m agnesium  sulfate, and evaporated 
under reduced pressure. The resulting yellow solid w as recrystallized 
from 95% ethanol to yield benz[/]indene in a 40% overall yield; m.p. 162- 
163 °C, lit m.p. 163-164 °C, aH NMR (200 MHz, CDCI3 ), 3.54-3.55 (d, 2H), 
6.63-6.67 (m, 1H), 6.97-7.00 (m, 1H), 7.29-7.87 (m, 6H)
4.3.4 Synthesis of Benz[/]inden-l-one.
Benz(/]ind.an-l-one (2.02 g, 11.1 mmol), NBS (2.17 g, 12.2 mmol), and 
benzoyl peroxide (20 mg) were refluxed in 20 mL of dry CCI4  for 2 hours. 
The solution was cooled, the succinimide removed by filtration, and the 
crude product was used directly in the next step. The crude brom inated 
product in CCI4  was cooled in an ice bath and triethylamine (1.93 mL, 13.9 
mmol) was slowly added. The m ixture was allowed to w arm  to room 
tem perature and stir overnight. A solid w as collected, purified  by 
sublimation and yellow crystals of benz[f]inden-l-one w ere obtained; 1H 
NMR (200 MHz, CDCI3) 6.11-6.14 (d, 2H), 7.30-7.95 (m, 6H); M+ 180.
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4.3.5 Synthesis of 2,3,6,7-Dibenzfluorenone.
a,a,a',a'-Tetrabrom o-o-xylene (0.468 g, 1.11 mmol) and benz[/]inden-l- 
one (0.200 g, 1.11 mmol) were dissolved in 10 mL of DMF. Sodium iodide 
(1.09 g, 7.22 mmol) was added and the m ixture stirred at 80 °C overnight. 
The reaction w as quenched in 25 mL of an ice /w a te r m ixture and 
decolorized w ith sodium  bisulfite. The resulting yellow precipitate was 
filtered and recrystallized first from glacial acetic acid, next from xylene, 
and  finally  sub lim ed  to  y ield  b righ t yellow  needles of 2,3,6,7- 
dibenzfluorenone in a 28% yield; m.p. 275-276, lit m.p. 269-270; NMR 
(200 MHz, CDCI3 ) 7.48-7.57 (m, 4H), 7.86-7.90 (t, 4H), 8.10 (s, 2H), 8.28 (s, 
2H), IR 1706.2 cm-1; M+ 280.
4.3.6 A ttem pted W olff-Kishner Reduction of D ibenzfluorenone.
2.3.6.7-Dibenzfluorenone (0.016 g, 0.057 mmol) and hydrazine hydrate 
(().991 g, 1.31 mmol) w ere placed in a sealed tube under vacuum  and 
heated to 205 °C for 24h. The resulting m ixture was sublim ed at 210 °C. 
NMR and MS showed no reaction.
4.3.7 A ttem pted W-7 Raney-Nickel Reduction of D ibenzfluorenone.
2.3.6.7-Dibenzfluorenone (0.021 g, 0.074 mmol) was dissolved in 50% 
aqueous ethanol and a 5 fold excess of W-7 Raney-Nickel was added. The 
m ixture refluxed overnight and extracted into ether. The organic layer 
w as dried over M gS04 and evaporated to yield a yellow solid. NMR
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show ed incom plete reduction. Longer reaction tim es d id  not give 
complete reaction.
4.3.8 A ttem pted Synthesis of benz[/lindenyl Iron(II)
Benz[/]indene (1.08 g, 6.5 mmol) was placed in a 100 mL Schlenk flask 
and placed under argon. 30 mL dry THF was added via cannulae. The 
m ixture was cooled to -78 °C and MeLi (0.143 g, 6.50 mmol) was added. 
The resu lting  dark  red  m ixture w as allow ed to w arm  to room  
tem perature. The solution w as added  slow ly to a suspension  of 
FeC l2 ;THF (0.881 g, 3.25 mmol) in 30 mL dry THF. After com plete 
addition, the mixture was refluxed overnight. The solvent was removed 
in vacuo. The resulting black solution w as extracted w ith  refluxing 
hexane. A fter allow ing the hexane soltion to cool, the solvent was 
rem oved in vacuo to yield a black solid. NMR showed the presence of no 
arom atic protons and MS also indicated that the extract contained no 
bis(benz[/]indenyl) iron(II).
4.3.9 A ttem pted Synthesis of Cp* benz[/|indenyl Ruthenium (II)
Benz(/]indene (0.135 g, 0.813 mmol) was dissolved in 10 mL dry THF 
under argon. To the stirred solution was added MeLi-LiBr (0.54 mL, 1.5 
M, 0.817 mmol). The pale yellow solution became crimson. After stirring 
for lh  at room tem perature, Cp*RuCl2 (0.10  g, .325 mmol) w as added 
under argon. The flask was fitted w ith a reflux condenser. The m ixture 
w as refluxed under argon overnight. The solvent was removed in vacuo.
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The residue was triturated w ith hot hexane and passed through a 10 cm 
alum ina colum n to rem ove insoluble particles. The filtrate w as 
evaporated to yield an orange solid. GC-MS show ed tw o peaks. The 
m ajor peak w as starting  m aterial and a very sm all peak  of a m inor 
p ro d u c t m atch ing  the  m olecu lar w eigh t of Cp* benz[/]indenyl 
ruthenium(II) M+ 402. While the mass spec showed evidence of formation 
of m inor am ounts of the desired product, NMR gave no evidence of 
aromatic protons. Only starting material could be seen.
4.6 Conclusions
The syntheses of these molecules are definite im provem ents over 
previous literature m ethods. N ot only are the yields are greater than 
literature, b u t the necessary num ber of steps w ere reduced as well.. 
C arpino 's synthesis of benz[/]indene w as the best synthesis of this 
molecule prior to our two syntheses. Yield was im proved from 11% to 
25% and 40%. We im proved the yield of 2,3,6,7-dibenzfluorenone as well. 
M artin's synthesis yielded 2,3,6,7-dibenzfluorenone in an overall yield of 
8 %. We obtained this ketone in a 28% overall yield via the Diels-Alder 
reaction. If 2,3,6,7-dibenzfluorenone can be successfully reduced, w e will 
have tw o novel cyclopentadienyl ligands for the synthesis of new  
metallocenes. A ttem pted syntheses of metal complexes have been less 
than successful. Synthesis of the iron complex failed completely. To date 
only the Cp* benz[/]indenyl ruthenium (II) complex has been formed. 
H ow ever, this molecule was form ed in extrem ely low yield w ithout
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isolation of any product. Varying the reaction conditions m ay lead to 
metal complexes in higher quantities.
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CD of (LysLeuAlaLysLysLeuAla) in Different Concentrations of
SDS Micelles
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CD of (LysLeuAlaLysLysLeuAla)2 in Different Concentrations of
SDS Micelles
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